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Muchos esfuerzos se han dedicado durante las últimas décadas a desvelar el intrincado puzle 
que conforman todos los papeles que juegan los ácidos nucleicos en los seres vivos. Los ácidos 
nucleicos no solo definen la constitución genética de un organismo sino que también participan 
en procesos enzimáticos y regulan la expresión genética. Por todo ello, existe un gran interés en 
el desarrollo de nuevas herramientas que puedan ser útiles en aplicaciones para diagnósticos o 
terapia basadas en estos procesos. 
Previamente, se ha sido establecido en el grupo OBCR (Organic and Biomimetic Chemistry) que 
la introducción de un grupo furano en un oligonucleótido puede logarse de forma sencilla 
utilizando síntesis automática. Como resultado se obtiene una sonda equipada con un grupo 
funcional altamente reactivo que ha sido enmascarado y es capaz, una vez que el grupo furano 
ha sido oxidado, de producir un entrecruzamiento entre cadenas de forma selectiva con la 
secuencia complementaria. La oxidación del grupo furano se puede lograr o bien usando NBS o 
bien, de una forma más biocompatible, usando oxígeno singlete. Para la formación de este 
último, los compuestos azul de metileno y rosa de bengala han sido estudiados en detalle.  
El objetivo de este estudio es expandir esta metodología al uso de fotosensibilizadores 
porfirínicos para la generación de oxígeno singlete con el objetivo final de desarrollar un método 
que se pueda aplicar en un contexto celular.  
Para ello, se seleccionaron tres fotosensibilizadores distintos: la clorina e6 (comercial), una 
porfirínica tripiridínica (TriPyCOOH) y una ftalocianina de zinc decorada con grupos tert-butilo.  
(TT1). 
 
Primero, se evaluó la habilidad de cada fotosensibilizador para producir el entrecruzamiento 
entre cadenas cuando se añaden en solución. Para ello, un oligonucleótido modificado con un 
grupo furano fue hibridado con la cadena complementaia en presencia del respectivo 
fotosensibilizador para evaluar la generación del entrecruzamiento una vez se produce la 
irradiacción necesaria. Una cuidados optimización de varios factores se llevó a cabo, incluyendo 
el tiempo de reacción, la concentración de los fotosensibilizadores, el ratio entre el dúplex y el 
fotosensibilizador y el tipo de luz utilizada. Fue hallado que de los tres fotosensibilizadores, el 
uso de Ce6 produce los rendimientos de entrecruzamiento más altos (conversión del 52%) 
cuando las condiciones son óptimas. TT1 fue capaz de producir el entrecruzamiento solo a bajos 
rendimientos, debido a su insolubidad en condiciones acuosas que son necesarias para esta 
reacción.  
 
En el siguiente paso, se planteó la hipótesis de que al conjugar los fotosensibilizadores a la 
cadena complementaria al oligonucleótido que contiene el grupo furano resultaría en dos 
mejoras importantes: la generación de oxígeno singlete se produciría cerca del grupo furano y 
la solubilidad en agua de los fotosensibilizadores sería mayor.  
Para conjugar cada fotosensibilizador se usó una estrategia de conjugación distinta, todas ellas 
basadas en la activación del ácido carboxílico en los fotosensibilizadores seguida por la adicción 
de un oligonucleótido que contiene un grupo amino. La conjugación de la TT1 fue 
particularmente problemática y esta reacción tuvo que llevarse a cabo con el oligonucleótido 
todavía en el soporte sólido donde se había sintetizado, para evitar el uso de condiciones 
acuosas y los problemas de solubilidad asociados.  
 
Una vez que los tres conjugados fueron sintetizados, se hibridaron al oligonucleótido que 
contiene el grupo furano y se evaluó la generación del entrecruzamiento. De nuevo, el 
entrecruzamiento que dio lugar a los rendimientos más altos fue en el que se usó el conjugado 
con Ce6, gracias una generación suficiente de oxígeno singlete y a una estabilización del dúplex 
que ocurre como consecuencia de introducir Ce6 en el oligonucleótido. Sorprendentemente, el 
uso del conjugado con TriPyCOOH no fue capaz de producir el entrecruzamiento, 
presuntamente debido la gran desestabilización que tiene lugar al introducir este 
fotosensibilizador y la pobre generación de oxígeno singlete. El conjugado con la TT1 mostró una 
alta generación de oxígeno singlete y fue capaz de producir el entrecruzamiento entre cadenas 
pero con rendimientos menores debido a una desestabilización del dúplex debido a la presencia 
del fotosensibilizador.  
 
Con la idea de permitir el entrecruzamiento con una secuencia no modificada, se sintetizaron y 
evaluaron sondas doblemente modificadas con un grupo furano y un fotosensibilizador. Sin 
embargo, la síntesis y el manejo de estas sondas auto-activables fue problemática, 
probablemente debido a la generación prematura de oxígeno singlete y la consiguiente 
desactivación de las sondas, y cuando la reacción de entrecruzamiento se intentó llevar a cabo 
no tuvo éxito en ningún caso.  
 
Como alternativa, se probó el uso de un sistema plantilla en el que el furano y el 
fotosensibilizador fueron introducidos en oligonucleótidos distintos y posteriormente 
hibridados a un oligonucleótido más largo sin modificaciones, que los mantiene próximos el uno 
al otro. Mientras que este enfoque tuvo éxito en un estudio anterior en el que se usaron sondas 
que contenían azul de metileno y rosa de bengala, en nuestro caso no pudimos demostrar la 
generación del entrecruzamiento. Debido a falta de tiempo, este enfoque no fue estudiado en 
más detalle ya que una tercera estrategia fue puesta en práctica (vide infra).  
 
En esta nueva estrategia se estudió el uso de un péptido de penetración celular como 
transportador. Los ácido nucleicos no son capaces de ganar acceso a las células y se ha descrito 
el uso de estos péptidos para terapias basadas en el uso de ácidos nucleicos ya que son capaces  
de asistir en la internalización de los ácidos nucleicos. En concreto, algunos de estos péptidos 
son capaces de formar complejos supramoleculares entre los péptidos cargados positivamente 
y los oligonucleótidos cargados negativamente, lo que resulta en la formación de 
nanopartículas.  
 En este caso, el uso del péptido conocido como MPG-8, que contiene 21 aminoácidos, se eligió 
para la formación de complejos con el oligonucleótido que contienen el furano. Al añadir la 
cadena complementaria y una concentración suficiente de Ce6 como fotosensibilizador, se 
observó la formación del entrecruzamiento, usando heparina para facilitar la liberación del 
oligonucleótido cuando es necesario. Posteriormente, MPG-8 fue conjugado a Ce6 y la 
formación del correspondiente complejo con el oligonucleótido que contiene el furano resultó 
en la formación de nanopartículas auto-activables que fueron capaces de producir el 
entrecruzamiento con un oligonucleótido no modificado.  
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Chapter I.  
Nucleic acids structure and relevance.  
Nucleic acid based diagnostics and therapeutics. 
 
I.1.  DNA structure  
DNA contains the genetic information necessary for all the processes that take place during an 
organism’s metabolism and this information can be transmitted to the next generation. DNA 
consists of a four letter ‘code’ where these four units, called nucleobases, are supported by a 
phosphate-sugar backbone. Two of these nucleobases are pyrimidine bases, cytosine (C) and 
thymine (T), whereas the other two are purine bases, adenine (A) and guanine (G). One molecule 
of DNA consists of two antiparallel strands where the nucleobases on one strand recognises the 
base on the opposite strand by hydrogen bonding: G pairs with C, A pairs with T, following 
Chargaff’s rules. The nucleobases also interact with each other by nonspecific  stacking due 
to their aromatic character, and the combination of those two forces holds the duplex together.  
 
Figure I-1. DNA structure. Reproduced with permission from (1) 
DNA duplexes have been observed in three different conformations: A, B and Z. The B-form is 
the most stable under physiological conditions, the A-form is found at low humidity conditions 
and the Z-form is the only characterised left-handed form of duplex and occurs only under 
particular conditions such as high salt concentrations.  
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Figure I-2. Different structures of double helical DNA. Incl. = inclination, x-Disp. = x-displacment, P-Tw = propeller twist. 
For Z-DNA, the helical parameters are given as averages of the alternating dinucleotide steps. Reproduced with 
permission from (1) 
 
I.2.  History of the discovery of DNA 
DNA was first isolated by F. Miescher in 1868 but it was not until the 1940s that the experiment 
performed by O.T. Avery, C. MacLeod and M. McCarty showed evidence that the genetic 
information encoding biomolecules it was DNA-based, and no protein-based. In this experiment, 
a non-virulent strain of Streptococcus pneumoniae was transformed into a virulent one by 
injection of DNA from a virulent strain of the same bacterium, showing that the genetic 
information for virulence was encoded in DNA.  In the same decade, E. Chargaff observed that 
the nucleobase composition varies from one species to another, but is constant within the same 
organism, indifferent to external factors like age or changing environment and, importantly, that 
the amount of A is equal to T, and G is equal to C.  
Another important clue that led to the discovery of the DNA structure was unraveled by R. 
Franklin and M. Wilkins in the early 1950s, using X-ray diffraction. From the pattern obtained it 
was inferred that DNA possessed a helical structure.  
Based on all this information J. Watson and F. Crick proposed their DNA model that was 
published in Nature in 1953 (2) and they were awarded the Nobel prize in Medicine or Physiology 
in 1962, together with M. Wilkins.   
 
I.3.  DNA metabolism 
The central dogma of molecular biology describes the flow of genetic information and it states, 
in a simplified manner, that the genetic information encoded in DNA is transcribed into 
messenger RNA (mRNA) which is then translated into proteins. 
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The whole picture, however, is much more complex. For example, mRNA is just one of several 
types of RNA that occur in cells: ribosomal RNAs are components of ribosomes and transfer 
RNAs participate in the translational machinery recognising the mRNA and adding amino acids 
to a growing peptide. More recently, the relevance of non-coding RNAs has only started to 
become apparent. Non-coding RNAs correspond to sequences that do not codify for any known 
protein but they have regulatory functions. They are classified according to their size: 18-25 
nucleotides for microRNAs and small interfering RNA, 20-300 nucleotides for small RNAs and 
between 300-10000 (or more) nucleotides that for medium and long non-coding RNAs.   
For example, the role of microRNA (miRNAs) in gene regulation has only been known since the 
early 1990s. (3) These noncoding RNA sequences, of around 22 nucleotides, play an important 
role in the regulation of mRNA, by repressing their translation or triggering cleavage. (4,5) 
 
Figure I-3. DNA metabolism including regulation processes by non-coding RNAs. Reproduces with 
permission from (6). 
The higher stability of DNA compared to RNA seems to be one of the reasons why DNA is the 
genetic ‘library’ in most organisms. However, DNA damage does occur, and it has been 
estimated that between 103 and 106 molecular lesions happen per cell per day. Cells have repair 
mechanisms to minimise the effects of these lesions as will be discussed in the following section.  
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I.4.  Repair mechanisms  
DNA damage has various origins such as the cell metabolism, due to reactive oxygen species 
produced (endogenous), environmental agents such as UV radiation (exogenous) or even errors 
during replication. In order to maintain the integrity of the genetic information, cells possess 
complex mechanisms that are able to minimise damage accumulation in their DNA. 
Understanding these repair mechanisms provides vital knowledge about living cells processes 
that can help in the development of for example new cancer treatments. In 2015, T. Lindahl, P. 
Modrich and A. Sancar were awarded the Nobel Prize in Chemistry for their works mapping 
different repair systems i.e base excision repair, nucleotide excision repair and mismatch repair.  
 
Figure I-4. Types of DNA repair.  
However, most repair mechanisms rely on the integrity of one of the strands of the DNA duplex 
since it is used as template to synthesise the new, error free strand section, after nicking the 
damaged fragment.  
However, there is a particular type of DNA lesions where both strands are involved by covalent 
linkage of two nucleobases on opposite strands, called interstrand crosslinks (ICLs). ICLs occur in 
the presence of exogenous agents and also by the formation of abasic sites(7), and there have 
been many efforts dedicated to the study of their repair processes as well as to the generation 
of site-specific and high yielding ICLs that allow their study.  
 
I.5.  Genotyping and discrimination of single point mutations. 
The genome of a given organism contains all information about their structure and metabolism 
and complete access to this information is key for understanding the origin of many diseases. 
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However, even within the same species there are genetic differences among individuals that 
account for the different characteristics that they display. The determination of those genotype 
differences, known as genotyping, finds application in many fields including biomedicine (8–10), 
molecular epidemiology (11,12) and forensics (13) among others.  
Several methods have been developed for genotyping including PCR and DNA sequencing. 
However, these methods are labour intensive and only a limited number of sequences can be 
investigated at a time. In recent years, the development of high throughput methods has 
attracted a lot of attention. For example, DNA arrays have been developed as a powerful tool 
that allows screening of a high number of DNA sequences (14,15), even an organism whole 
genome. As they rely on DNA hybridisation, they are inherently limited by the specificity of 
hybridisation and interrogation of complex samples is cumbersome, particularly when 
differences are as small as one nucleotide, as in single nucleotide polymorphisms (SNPs).(13,16–
18) 
Single stranded DNA (ssDNA) detection typically relies on different detection methods, (19) 
including fluorescence, (20–22) electrochemistry (23,24) and more recently nanoparticle-based 
detection, particularly Au NPs. (25–29) 
Some of these methods allow detection at femtomolar concentrations, however the aim is to 
detect at the single biomolecule level avoiding the use of PCR for amplification (30,31) 
Recently, some examples of crosslinking-assisted point mutation detection have been reported, 
showing the potential of crosslinking methodologies not only for repair mechanisms study but 
also for sequencing and diagnosis applications. Greenberg at al. described the use of bifunctional 
ODNs that induce crosslink formation under mild oxidation conditions towards a 16-nt long sites 
on plasmid DNA with a point mutation. Fluorescence based detection allowed probing of the 
target sequence at nanomolar concentrations. (32) 
Moreover, the group of Fujimoto showed the potential of the use of photocrosslinking molecular 
beacons for detecting SNPs in a dsDNA context. The crosslinking formation stabilised the 
complex formed between the molecular beacon and the target, allowing strand displacement 
or invasion of the duplex. (33)  
I.6.  DNA based therapeutics 
Nucleic acids and derivatives thereof have been used for therapeutic applications to target 
different biomolecules:  
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 In the antigene strategy, the aim is to modulate gene expression and the use of triplex 
forming oligonucleotides (TFOs) has been described. (34) Such TFOs are sequence 
specific, binding the target duplex through the formation of Hoogsteen bonds. The 
successful in vitro and in vivo use of this method has been reported (34) but their clinical 
application is hampered by the rare occurrence of the polypurine or polypyrimidine 
sequences that are required for the formation of the triplex.  
 Another approach consists in the targeting of transcription factors which are responsible 
for transcription of DNA into mRNA. The use of a decoy duplex DNA competes with the 
targeted promoter thus influencing the transcription levels. (35) The use of polyamides 
has been described as an alternative to the use of dsDNA since polyamides are able to 
easily diffuse into the nucleus. (36–38) 
 On the other hand, targeting mRNA instead of DNA shows the advantage that access to 
the nucleus is not necessary. Also in this case, the use of decoy oligoribonucleotides has 
been reported, which compete for the proteins involved in the translation. (39,40)  
 Also targeting mRNA, the use of the so-called antisense strategy relies on the delivery 
of a complementary sequence that results in the formation of different complexes with 
the mRNA and at last inhibits translation. (41,42) Several approaches have been 
explored, including interference with the splicing of RNA into mature mRNA, (43,44) 
recruitment of RNaseH (45,46), ribozymes (47,48) or DNA enzymes (49,50), which 
results in the cleavage of the mRNA, or the steric blockage of the mRNA preventing 
translation. (51,52)  
However, the reversible nature of the duplex hybridisation between the targeted nucleic 
acid and the therapeutic nucleic acid is disadvantageous and the formation of a covalent 
bond between the two strands has been recently shown to enhance the antisense effect. 
(53–56) 
I.7.  ICL generation methodologies 
The damage that ICLs inflict to DNA forms the basis of the use of many chemotherapeutic drugs 
and also chemical weapons. However, in the case of the therapeutic use, the lack of selectivity 
of chemotherapeutic drugs such as mitomycin C, nitrogen mustard and cisplatin is the reason 
for their detrimental secondary effects.  
Chemistry provides a valuable tool for the generation of more selective ICLs as it allows the 
introduction of unnatural moieties into synthetic oligonucleotides for a site-specific and 
controlled generation of ICL. Among all the ICL approaches, most crosslinking probes rely either 
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on alkylation, [2+2] cycloadditions or the use of masked carbonyl functionalities for the ICL 
formation.  
I.7.1.  Alkylation based ICL formation 
 Alkyl halides 
Although alkylation based ICL formation has been carried out using highly reactive 
moieties such as unprotected alkyl halides, (57–59) the inherent reactivity of these 
functionalities (figure I-5a and b) may result in off-target reactions and are unsuitable 
for biological applications. Attempts to achieve a more biocompatible methodology 
have been made by the group of Luedtke, which reported the use of a O6-(2-
chloroethyl)guanine residue containing a photolabile ortho-nitrobenzyloxycarbonyl 
(NBOC) group at the N2 position (Figure I-5c). NBOC acts as an electron-withdrawing 
group stabilising the chloroethyl moiety until is deprotected by irradiation at 365nm. An 
intramolecular reaction results in a highly reactive cyclic cation that can alkylate a 
cytosine base on the opposite strand. The crosslinked adduct possess an analogous 
structure as the crosslinking formed using the chemotherapeutic agent BCNU. (60) 
 
Figure I-5. Examples of alkyl halides for ICL formation. 
 
 Strained systems 
One of the first approaches for ICL formation was the use of nucleosides containing 
conformationally strained rings (figure I-6a) or heterocycles such as aziridine (figure I-
6b) (61,62) or a cyclopropapyrroloindole. (63) Recently, the group of Kobori reported 
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the synthesis of a 2’-O-diazirine-conjugated adenosine that undergoes ICL formation 
towards DNA upon UV irradiation (figure I-6c). (64)  
 
Figure I-6. Synthetic nucleosides containing strained rings.  
 Vinyl-modified nucleotides  
Sasaki et al. have described the synthesis of vinyl containing nucleosides that allow 
selective target of different nucleobases situated on the opposite strand. The use of a 
2-amino-6-vinylpurine nucleoside allowed to produce selective ICL formation towards 
cytidine that was triggered by hybridisation. They showed the beneficious effect of 
masking the double bond as a phenyl sulfoxide, which resulted in higher crosslinking 
yields compared to the unmasked vinyl group. (65) 
 
Figure I-7. ICL formation between a 2-amino-6-vinylpurine and cytosine. 
 
On the other hand, when a 4-vinylpirimidine-2-one nucleoside was used in the context 
of RNA or duplex DNA crosslinking, selectivity was towards adenine or uracil, depending 
on the target sequence and the reaction conditions. (66) This methodology was also 
applied in biological systems by enhancing antisense effects. (66–68) 
Moreover, the group of Greenberg described the use of selenide derivatives that upon 
oxidation, via NaIO4 or singlet oxygen (69), result in alkylating agents via a [2,3]-
sigmatropic rearrangement and were applied for SNP detection. (32,70) 
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Figure I-8. Generation of ICL precursor via oxidation and crosslinking towards adenine. 
 
 Radical precursor nucleotides 
Greenberg et al. described the first radical-based method for ICL formation by using aryl 
selenide or sulphide derivatives as radical precursors that can be activated using 
photochemical activation, thermal activation. (71) The exact mechanism of radical 
generation and ICL formation was elucidated.(72) 
 
Figure I-9. ICL formation via a radical intermediate.   
 
I.7.2.  [2+2] cycloaddition 
One of the damaging processes that DNA undergoes consists in a [2+2] cycloaddition between 
two adjacent thymidines when exposed to UV light. The 5,6-double bond of pyrimidine 
nucleobases is susceptible of a [2+2] cycloaddition not only by another nucleobase but also by 
exogenous agents. Introduction of such compounds into oligonucleotides results in light 
triggerable crosslinking probes, and three main type of compounds have been used with this 
purpose: 
 Coumarins 
The group of Peng reported for the first time the synthesis of a coumarin containing 
ODNs that undergo reversible ICL formation (350/254nm irradiation) with an opposite 
dT or dC (73). Real time ICL monitoring by fluorescence was achieved after optimisation 
of the position and type of linker used to introduce the coumarin in the ODN. (74)  
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Figure I-10. General mechanism for coumarin based ICL.  
 
 Psoralen 
Psoralens are closely related to coumarins, consisting of a furan ring that is fused to the 
bicyclic coumarin skeleton, and can also undergo [2+2] cycloadditions upon UV 
irradiation. The group of Murakami showed that introduction of a psoralen derivative at 
the 5’ end of a ODN methylphosphonate results in ICL formation with the base on the 
complementary strand when irradiated at 365nm, and it was highly dependent upon 
the fidelity of base pairing (75) and was later on shown to be able to inhibit translation 
of mRNA in a cell-free medium. (53) 
 
Figure I-11. General mechanism for psoralen based ICL. 
 
The use of phosphorothioate derivatives was explored and applied to inhibit the 
proliferation of human cervical carcinoma cells (76) and also as a decoy for restriction 
endonucleases(77) or estrogen receptors. (78) Also, the use of a hairpin conformation 
allowed a better sequence specificity when used for RNA crosslinking. (79) 
 
To broaden the targeted sequences repertoire, a dA nucleoside decorated with the 
psoralen moiety at the 2’ position was synthesised and resulted in an enhanced 
sequence specificity compared to the 5’ modified ODN. (80,81) These ICL probes were 
effective for antisense strategy by inhibit K-ras-immortalized cell proliferation (82) and 
for RNA-induce silencing complex regulation by targeting microRNA. (54) 
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 Cyanovinylcarbazole 
The group of Fujimoto developed a crosslinking strategy based on a 3-
cyanovinylcarbazole nucleoside that allows an ultrafast reversible ICL formation with 
pyrimidine bases upon UV irradiation (366/312nm) and the crosslinking formation was 
explored in the context of DNA/DNA and DNA/RNA duplexes. (83,84) This methodology 
has been applied to antisense strategy, (55,85) detection of SNPs (33) and stabilisation 
of nanostructures. (86–88) 
 
Figure I-12. Reversible ICL formation using a 3-cyanovinylcarbazole nucleoside.  
 
1.1. Masked carbonyls 
The susceptibility of carbonyl groups towards nucleophilic attack can be exploited for ICL 
formation. However, introduction of a carbonyl functionality into synthetic ODNs is troublesome 
and different strategies for masking the carbonyl groups have been used. Kobori et al. developed 
ODNs containing caged -chloro- and -bromoaldehyde moieties at the 5’ end that are 
activated by UV irradiation and induce ICL formation (Figure I-13a) (89,90). Introduction of the 
caged carbonyl at different positions in the ODN was later achieved and applied for crosslinking 
formation with RNA having a point mutation (Figure I-13b). (91) 
 
Figure I-13. Protected carbonyl groups introduced into ODNs. 
An analogous protecting group was used for the introduction of a 4-oxo-enal functionality into 
an ODN that selectively formed an ICL towards T and G. (92) 
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Figure I-14. Introduction of a 4-oxo-enal functionality using two different protecting gorups. 
The furan methodology developed by our group falls into this category of masked carbonyls as 
furan can be seen as a stable precursor of a 4-oxo-enal which is unmasked upon oxidation. 
It is worth noticing that many of these methodologies rely on the use of UV light for activation 
as this allows spatiotemporal control of the ICL formation. However, UV irradiation can promote 
the formation of thymidine dimers in DNA and is not the most suitable for therapeutic 
applications as it can damage surrounding tissues. For this reason the use of longer wavelength 
light for irradiation is desirable.  
 
I.8.  Furan as a masked functionality for ICL formation 
Our group developed a strategy for ICL formation that took inspiration from furan toxicity. Upon 
metabolism in the liver by cytochrome P450 furans are transformed into reactive intermediates 
that can react with nucleophiles or further rearrange to form a cis-enedione, which is also 
susceptible to nucleophilic attack by different biomolecules. This is the reason for furan toxicity, 
especially kidney and liver toxicity, and therefore, furan is classified as a carcinogen by the IARC. 
(93,94) 
 
Figure I-15. Furan metabolism by cytochrome P450.  
This susceptibility towards nucleophiles makes furan an ideal candidate for ICL as nucleobases 
contain nucleophilic groups that can react with the oxidised furan. Therefore, several furan 
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containing building blocks were developed by our group during the last years and they all can 
be easily incorporated during standard solid phase synthesis of oligonucleotides. (95–100)  
The scope of the furan methodology has been explored in the context of crosslink formation in 
duplex DNA (98,100,101), duplex RNA (102), triplex forming ODNs (103), furan-PNA towards 
single and double stranded DNA (104). The versatility of this strategy allows it to be even applied 
for DNA-peptide crosslinking (105) and peptide labelling. (106) 
The building blocks used for ICL formation in DNA or RNA showed selectivity towards (d)A or 
(d)C by reacting with their exocyclic amines. Although (d)G contains an exocyclic amine it is not 
oriented towards the major group hampering the formation of ICL formation. Last, dT or U do 
not have any exocyclic amine that can react with the oxidised furan and ICL formation with this 
nucleobases was never observed.  
 
Figure I-16. Building blocks containing a furan moiety.  
The crosslinking mechanism consists in the attack of the exocyclic amine to the aldehyde yielding 
a hemiaminal that undergoes cyclisation upon attack of the endocyclic nitrogen to the Michael 
acceptor that resulted after furan oxidation. The crosslinking reaction, depicted here (Figure I-
17) for ICL towards dC, may stop at this point or proceed to form an aromatic adduct after losing 
a molecule of H2O, depending on the furan building block of choice. During this study, building 
blocks 2 and 5 were used. Upon use of 5, the reaction stops before aromatisation, whereas when 
using 2, the aromatic adduct is obtained. It is worth noticing that when the ICL formation stops 
before aromatisation, the presence of two stereocentra results in the formation of 
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diasteromeric adducts that can be observed as two distinct signals by RP HPLC, as will be shown 
in the next chapters.  
 
Figure I-17. Crosslinking mechanism between the oxidised furan and a cytosine on the complementary strand. 
Two different triggers have been reported for furan ICL formation. First, the use of NBS results 
in the addition of a bromide to the 2 position of furan, followed by attack of a molecule of H2O 
(figure I-18a). The ring opening leads to the formation of the 4-oxo-enal. Although effective, this 
activation method prevents the use of the furan methodology for biological applications and in 
some cases presents a side product resulting for the bromination of furan, which decreases the 
overall yield. Therefore, the use of a more biocompatible oxidant was envisioned and 
photosensitised singlet oxygen was the chosen agent.  
 
Figure I-18. Mechanism of furan oxidation by NBS and singlet oxygen.  
Singlet oxygen-mediated oxidation of furan follows a different mechanism to NBS and consists 
of a [4+2] cycloaddition between the furan and the oxygen molecules. Addition of a H2O 
molecule and rearrangement leads to the open 4-oxo-enal (figure I-18b). (107,108) 
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I.9.  Properties and generation of singlet oxygen 
Ground state oxygen is a paramagnetic molecule where two electrons with parallels spins 
occupy two different * orbitals. Since most organic molecules are diamagnetic, there is a spin 
restriction for reactions where oxygen accepts more than one electron at a time. 
Excitation of molecular triplet oxygen (3O2) results in the formation of a more reactive oxygen 
species, the so-called singlet oxygen (1O2), where the two electrons possess opposite spins. Since 
the spin restriction is removed, 1O2 is more oxidising than 3O2 (1V) and reacts with molecules 
such as unsaturated C-C bonds, neutral nucleophiles and anions, which makes it a versatile 
synthetic reagent. (109) 
 
Figure I-19. Molecular orbitals diagrams for 3O1 and 1O2 
1.2. Singlet oxygen generation 
In 1926, Moureau and Dufraisse discovered that the aromatic compound rubrene (Figure I-20a) 
is able to covalently bind oxygen, and that this process is reversible, producing 1O2 and 3O2 when 
it decomposes. Since then many aromatic compounds have been described to undergo a 
reversible [4+2] cycloaddition with O2. (110) MNP and the corresponding endoperoxide MNPO2 
are the only ones that require a mild activation such as (Figure I-20b). (111) These compounds 
are poorly water soluble (10-2 M at pH 7.5) but this problem was overcome by introducing a 
second sodium propylcarboxylate group in NDPO2 and NDP, (111) and these compounds are 
widely used in biological environments to generate controlled amounts of 1O2.  
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Figure I-20. Singlet oxygen reversible reaction with aromatic compounds. 
 
However, the most common mechanism for 1O2 generation is by means of a photosensitiser 
(PS). PSs are compounds that are able to harvest light and transfer the energy to another 
molecule, in this case to 3O2. As depicted in figure I-21 upon light irradiation the PS goes to the 
excited singlet state where it can deactivate via a radiative (fluorescence) or non-radiative 
process or, by intersystem crossing, lead to the triplet state PS. This 3PS is able to interact with 
3O2, generating 1O2 in what is known as Type II mechanism, whereas deactivation via Type I 
mechanism involves electron and/or proton transfer and leads to the generation of other 
reactive oxygen species (ROS) such as hydroxyl radical (·OH), superoxide anion (O2·-) and 
hydrogen peroxide (H2O2).  
 
Figure I-21. Jablonski diagram for ROS generation. Reproduced with permission from (109) 
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1.3. Singlet oxygen applications 
 
 As reagent in organic synthesis 
The electrophilic character of 1O2 determines the type of reactions that it can undergo 
and those can be divided in three classes: a) ene reactions, b) [4+2] and [2+2] 
cycloadditions and c) reactions with heteroatom centres.  
a) Ene reactions consist in the addition of a molecule of 1O2 to a sp2 carbon of 
an alkene substrate and abstraction of hydrogen from a distal allylic carbon, 
resulting in an allylic hydroperoxide.  
 
 
Figure I-22. Ene reaction. 
 
b) [4+2] and [2+2] cycloadditions 
The [4+2] cycloaddition (figure I-23a) between a rich cis-diene and 1O2 is 
analogous to the Diels-Alder reaction where an endoperoxide is formed, in 
a stereospecific manner. Different types of dienes can be used such as 
acylic, cyclic, polyaromatic, or hetero- atomatic 
In [2+2] cycloaddtions (figure I-23b), dioxoetanes are formed by addition of 
1O2 to an electron rich alkene. However, the formation of the [4+2] and ene 
reaction products as contaminants is common.  
 
 
Figure I-23. Singlet oxygen cycloadditions  
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c) Reactions with heteroatom centres 
Reaction between 1O2 and heteroatoms have been studied with a variety of 
heteroatom containing organic molecules including: organosulfur 
compounds, phosphines, nitrogen compounds and some organometallic 
complexes. However, the efficiency of the reaction is low, since the physical 
deactivation of the intermediates competes to result in 3O2 and the original 
substrate (figure I-24) 
 
Figure I-24. Example of a reaction between 1O2 and an organosulfur compound and the 
competing deactivation 
 
 Photodynamic therapy. 
Photodynamic therapy (PDT) is the use of a combination of light, oxygen and a 
photosensitiser for producing a therapeutic effect and it relies on the generation of ROS, 
especially 1O2. Those three elements do not individually exert a therapeutic effect but 
in combination, result in a versatile technique for treating various diseases such as 
cancer, psoriasis, dermatitis, etc. (112) Closely related, ROS can be used for elimination 
of microorganisms in the so called antimicrobial PDT (aPDT). (113,114) 
 
Figure I-25. Oxygen, light and photosensitiser are the components needed for PDT. 
One of the main drawbacks of PDT comes from the need of light irradiation which limits 
the widespread clinical use of PDT (115) and several strategies have been followed 
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recently to overcome this issue. For example, the design and synthesis of 
photosensitisers that absorb in the near infrared region (NIR) allows to expand the 
possibilities for treatment of malignancies situated deeper in the organisms. Two 
photon absorbance PDT has been very promising and self-irradiating compounds have 
been designed as well. (116,117) 
Many types of PSs have been used for 1O2 generation and they can be classified into 
porphyrin and non-porphyrin based. As dark toxicity can be a problem, porphyrin 
based molecules, which are devoid of that problem, have come into play. Porphyrins 
are aromatic macrocyclic compounds that strongly absorb in the visible part of the 
electromagnetic spectrum. They can exist as the free base, where no metal is 
coordinated by the four nitrogen atoms in the central cavity, or metallated with a 
variety of metal atoms. Closely related to porphyrins, chlorins possess the same 
aromatic core but one of the double bonds is reduced. If two of the double bonds have 
been reduced they receive the name of bacteriochlorins. Phthalocyanines possess 
extra nitrogens in the meso positions and benzene rings to the pyrroles.  
 
Figure I-26. General structure of a) porphyrins b) chlorins c) bacteriochlorins and d) phthalocyanines. 
For PDT applications, many different PSs have been reported and studied, trying to 
improve their properties such as absorption, 1O2 quantum yield, biocompatibility, 
solubility, etc. The first PS approved for clinical use was a synthetic polymer derived 
from haemotoporphyrin (Hp), commercialised under the name of PhotofrinTM. 
However, this compound is actually a complex mixture of monomers and oligomers 
and its absorption in the therapeutic window is low (1170 M-1 cm-1 at 630 nm) requiring 
higher doses of the drug to induce an effect. For this reason, a second generation of 
PSs was developed where the absorbance in the red region of the electromagnetic 
spectrum, more interesting for clinical application, was improved. Chlorins, 
phthalocyanines, texaphyrins, etc are among these compounds. Development of the 
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third generation PSs focusses on improving the specific targeting of the PS, for example 
by conjugation to antibodies, ODNs, etc. (118) 
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Chapter II. 
Aims and objectives  
 
Nucleic acids have been exploited as versatile compounds in diverse fields for diagnosis, therapy 
and nanomaterial applications. Introduction of an interstrand crosslink has proven to offer great 
potential for enhancing the properties of nucleic acids or providing them with new 
characteristics, and a variety of crosslinking techniques have been developed, as described in 
the previous chapter. However, in some of those applications the use of a mild, spatiotemporally 
controlled activation of the crosslinking is desirable. In this context, the use of the furan 
methodology coupled with the triggering of the reaction via singlet oxygen allows efficient 
crosslinking under biocompatible conditions, as has been previously stablished using methylene 
blue and rose bengal.  
In this study the generation of singlet oxygen is achieved using three porphyrin-based 
photosensitisers. Chlorin e6 (Ce6), a tripyridyl porphyrin (TriPyCOOH) and a zinc phthalocyanine 
decorated with tert-butyl groups in the periphery (TT1) have been evaluated for singlet oxygen 
generation to induce interstrand crosslink formation.  
 
It was previously established that the use of singlet oxygen in a nucleic acid context requires fine 
tuning of the reaction conditions to maximise the crosslink formation without undesired 
degradation of the duplex. For this reason, the first step during this work was to study the 
crosslink reaction with the photosensitisers added in solution in the presence of the duplex, 
where one of the strands contains the furan moiety. Variation of the concentration, reaction 
time, light type, etc will be explored and optimised to maximise the crosslink formation while 
minimising degradation.  
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Once these conditions will be established, we hypothesise that conjugation of the 
photosensitisers to an oligonucleotide can have two important advantages: the solubility in 
aqueous conditions of the photosensitisers is improved and singlet oxygen is generated in close 
proximity to the furan moiety, minimising off-target reactions. Therefore, each dye will be 
conjugated to the furan oligonucleotide complementary strand, and the crosslink formation will 
be evaluated using these compounds.  
However, this system does not allow targeting of natural unmodified sequences, preventing the 
use of the furan methodology for potential therapeutic applications. For this reason, a self-
activating probe, where the photosensitiser and the furan moiety are introduced in the same 
oligonucleotide is envisioned. The synthesis and handling of such double modified probes might 
be problematic, and therefore as an alternative, the use of a templated system where a furan 
and a photosensitiser oligonucleotide together target a longer, unmodified sequence will be 
explored. Indeed, this kind of system showed promising results when the photosensitiser of 
choice was methylene blue or rose Bengal.  
 
Finally, the use of a cell penetrating peptide as carrier for the furan modified oligonucleotide is 
envisioned. These compounds are able to complex nucleic acids by electrostatic interactions 
between the positively charged peptide and the negatively charged oligonucleotides, resulting 
in the formation of nanoparticles that can gain access inside cells while protecting the integrity 
of the nucleic acid. Moreover, conjugation of a photosensitiser to the peptide should result in 
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the formation of a self-activating nanoparticle that allows the targeting of unmodified nucleic 
acid sequences and the photosensitiser delivery at the same time as the furan oligonucleotide.  
 
To summarize, several aims were set for the study of porphyrin-based photosensitisers for 
interstrand crosslink formation: 
 Optimisation of the conditions for the use of these compounds for interstrand 
crosslinking in solution. 
 Conjugation of the photosensitisers to oligonucleotides and evaluation of their potential 
to induce crosslinking formation with a complementary furan strand. 
 Construction of a self-activating system that allows targeting of unmodified sequences.  
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Chapter III.  
Crosslinking experiments using porphyrin-based 
photosensitisers in solution 
Part of this work was published in: 
Porphyrin-based photosensitizers and their DNA conjugates for singlet oxygen 
induced nucleic acid interstrand crosslinking, Org. Biomol. Chem., 2017 
 
In this chapter three different porphyrin based photosensitisers are 
selected and evaluated in solution for their capacity to induce DNA 
interstrand crosslink formation. A chlorin, a porphyrin and a 
phthalocyanine are evaluated under different conditions changing 
parameters such as the photosensitiser/ODN ratio, type of light, 
reaction times and furan building block. It was clear from this study 
that an optimisation of the reaction conditions is necessary for each 
different system to obtain optimal ICL formation.  
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III.1. Synthesis of furan modified ODNs 
In this study, building blocks 1 and 2 (figure III-1) were evaluated. Building block 1 was reported 
to induce a higher crosslinking yield upon oxidation with NBS rather than 1O2. (1) However, 
during this previous study the irradiation conditions were not optimised for this building block, 
which could explain the lower yields obtained. Building block 2 was shown to produce 
crosslinking yields up to 57%, determined by RP HPLC analysis, when the conditions where 
optimised for the use of MB for 1O2 generation. We here aimed at the full optimisation and 
comparison for both building blocks.  
 
Figure III-1. Furan building blocks evaluated during this study. 
Synthesis of the furan modified ODNs was carried out by automated solid phase synthesis using 
phosphoramidite chemistry, apart from the incorporation of the furan building block which was 
achieved by manual coupling. During the solid phase synthesis, one nucleotide is added per 
synthesis cycle to a growing chain that is linked to a controlled-pore glass (CPG) solid support 
via the 3’ terminus (figure III-2). The high yields obtained when using this technique results from 
the use of several protecting groups that prevent side reactions: the 5’-OH of the nucleotides 
are protected using a dimethoxyltrityl (DMT) group, the exocyclic amino groups of the 
nucleobases are protected using benzoyl (dA and dC) or isobutyryl (dG) groups and the 
phosphate groups are protected as 2-cyanoethyl phosphotriesters.  
At the start of the synthesis, removal of the DMT group of the first nucleotide, which is usually 
already attached to the CPG, is achieved using trichloroacetic acid (TCA) in DCM. Throughout 
the synthesis, the detritylation step results in the formation of the brightly orange trityl cation, 
which can be used to monitor the coupling of the nucleosides.  Subsequently, the next 
nucleoside phosphoramidite is mixed with tetrazole, which activates it towards the nucleophilic 
attack by the 5’-OH of the previous nucleoside. 
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 Figure III-2. Schematic representation of the automated solid phase synthesis of ODNs.   
In spite of the high yields of the coupling reaction (up to 99.5%), any unreacted chains would be 
available in the next cycle for incorporating the next nucleoside, leading to deletion sequences. 
To prevent the formation of a complex mixture of different deletion sequences, a capping step 
is included after the coupling that blocks the unreacted 5’-OH. During the capping, a mixture of 
acetic anhydride and N-methylimidazole (NMI), containing pyridine to maintain the basic pH to 
avoid detritylation, is used to acetylate the unreacted 5’-OHs.  
Finally, oxidation of the phosphitetriester using iodine in the presence of water and pyridine 
leads to the formation of the phosphotriester bond and the cycle starts again with the 
detritylation of the 5’-OH of the last incorporated nucleoside.  
For the introduction of the furan building block, the corresponding phosphoramidite was 
synthesised from the DMT-protected precursor 24 h before the ODN synthesis was carried out, 
to minimise hydrolysis of the sensitive phosphoramidite moiety (figure III-3). During the 
automated synthesis, the synthesiser is interrupted just before the coupling step. Then, a 
solution containing the furan-modified phosphoramidite and a dicyanoimidazole (DCI) solution 
are alternately applied. DCI is used instead of tetrazole to maximise the coupling of the furan 
building block, in view of its higher reactivity compared to tetrazole. After applying a capping 
step, the automated synthesis is resumed.  
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Figure III-3. Example of the phosphoramidite synthesis previous to the automated synthesis using building block 1.  
At the end of the synthesis, the last trityl group of the synthesised ODN can be kept (DMT on) to 
be used as a handle during reverse phase purification: the increased hydrophobicity that the 
DMT confers allows a better separation between the desired strand and the deletion sequences 
that do not contain the DMT group.  
When the synthesis is completed, the obtained ODN is deprotected and cleaved from the CPG 
by treatment with NH4OH at 55ºC. Subsequent purification can be carried out by different 
methods. Our purification method of choice consists in the use of reverse phase cartridges 
where, upon loading of the reaction mixture after deprotection, the DMT-ODNs are retained in 
the cartridge, whereas the deletion sequences and protection groups are eluted. Treatment with 
trifluoroacetic acid (TFA) results in the cleavage of the DMT group allowing elution of the desire 
ODN.  
Two different furan containing ODNs were synthesised using the two different furan building 
blocks (table III-1) and their crosslink generation abilities will be evaluated and compared in this 
chapter.  
Table III-1. Furan containing ODNs used during this study.  
Name Sequence (5’-3’) Modification 
FON1 CTG ACG GXG TGC X= 1 
FON2 CTG ACG GXG TGC X= 2 
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III.2. Crosslink formation with a PS in solution 
Three PSs have been evaluated: chlorin e6 (Ce6), TriPyCOOH porphyrin and TT1 phthalocyanine 
(figure III-4). These porphyrin-based PSs have very different spectroscopic properties as can be 
observed in figure III-5. Porphyrins present an intense absorption band around 400 nm, the so 
called Soret band, and some less intense bands around 500-700 nm, known as Q bands; chlorins 
also present an intense Soret band but have an improved absorption around 650 nm compared 
to porphyrins; on the other hand, the main absorption of phthalocyanines appears at 600-800 
nm.  
 
Figure III-4. PSs evaluated during this study: chlorin e6, TriPyCOOH porphyrin and TT1 phthalocyanine. 
Apart from the different spectroscopic properties, differences in the core decoration results in 
a different hydrophilic/hydrophobic character of the PS. Moreover, the phthalocyanine 
extended aromatic system makes these compounds very prone to aggregation. Keeping these 
factors in mind we carried out an evaluation of these PSs in an ICL context under conditions as 
biocompatible as possible e.g. minimising the presence of organic solvents and prioritising the 
use of red light and the optimised conditions for each PS are reported.  
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Figure III-5. Depiction of generic spectroscopic features of a) porphyrins, b) chlorins and c) phthalocyanines, and the 
tissue penetration of different types of light. Reproduced with permission from (2) 
During the optimisation process to find optimal conditions for ICL formation for each PS, the 
duplex FON1-ON1 was used (table III-2). Previously, it was established that this furan building 
block is able to induce ICL formation towards dA and dC, particularly the latter, in spite of this 
combination resulting in a mismatch. Therefore, the complementary sequence ON1 contains a 
dC opposite to the furan building block.  
Table III-2. Furan modified strand (FON1) and its complementary sequence (ON1) used during the following 
crosslinking experiments. 
Name Sequence 
FON1 5’ - CTG ACG G1G TGC - 3’ 
ON1 3’ - GAC TGC CCC ACG – 5’ 
 
The use of this duplex results in the generation of a diastereomeric mixture since the reaction 
does not proceed to aromatisation (figure III-6), and the crosslinked adducts are observed as 
two different signals by RP HPLC.  
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Figure III-6. Generation of a crosslinked adduct towards dC that consists of a diastereomeric mixture.  
III.2.1. Chlorin e6 as a photosensitiser 
First, chlorin e6 (Ce6) was evaluated. Ce6 is a commercially available, second generation PS 
that can be harvested from green algae species (Chlorella ellipsoidea) (3) and has been widely 
used for photodynamic therapy (PDT), (4–6) including conjugated to aptamers for targeted 
PDT (7–9) and derivatised with an aspartyl moiety. Mono-L-aspartyl Ce6, also known as 
Talaporfin or NPe6, is approved in Japan for lung cancer treatment. (10,11) 
Chlorins present a rather strong absorption around 650 nm (667 nm in ethanol for Ce6) that 
ensures a sufficient light absorbance if red light is used for irradiation and therefore this will 
be the light type of choice. The dye was dissolved in DMSO and added to the reaction mixture 
(1% final DMSO content) just before irradiation to the duplex in phosphate buffer solution. 
Samples were taken at different irradiation times for subsequent analysis by RP HPLC and 
PAGE. The crosslink reaction was carried out at a concentration of 2 or 20 M of the duplex. 
By also evaluating the ICL formation at lower duplex concentration, we attempted to use 
more biologically relevant concentrations and to establish a comparison point for the later 
use of the PS conjugated ODN (chapter IV). At this concentration, a 1:1 duplex/PS ratio was 
used. When a 20M concentration of the duplex was used, the PS was added at 5 and 10M. 
The ICL formation was fast and already after 5 min the crosslinking yield reached a plateau 
or started to decrease (figure III-7a). The used of an equimolar duplex/PS ratio resulted in the 
highest yields (52%, figure III-7b) as determined by integration of the peak areas of the two 
signals at 14.5 min in the HPLC chromatogram, corrected by the corresponding extinction 
coefficient of each ODN and duplex, which have been previously identified as the crosslinked 
adduct when the aromatisation does not proceed. (12) The crosslink formation was 
confirmed by PAGE, as a slower migrating band can be observed after irradiation, which 
indicates the presence of a higher molecular weight species, which under denaturing 
conditions is believed to correspond to a crosslinked adduct. The appearance of this species 
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is concurrent with the consumption of the ON1 and FON1 signals and was previously 
characterized by MS analysis during earlier work.. 
 
Figure III-7. ICL formation using Ce6 as PS. a) Summary of the crosslinking yields at 3 different ratios. b) RP HPLC 
analysis  of the ICL experiment where [duplex]=[Ce6]=2 M (XBridge column, linear gradient of 0-20% ACN in 30 
min); c) PAGE analysis of the same experiment (20% polyacrylamide, 1x TBE buffer, GelRedTM used for staining). 
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Moreover, to assess the versatility of this PS, ICL formation was evaluated using no DMSO or a 
higher amount (20%), but either case does not have a large influence in the ICL generation as it 
can be observed in figure III-8. Increasing the amount of DMSO under otherwise optimised 
conditions for ICL formation using Ce6 only seemed to slightly slow down the crosslinking 
formation, but similar yields were obtained. When no DMSO was used at a lower duplex/Ce6 
ratio, the crosslink was formed at the same extent as when 1% DMSO was added, indicating no 
significant quenching in the 1O2 generation.  
 
Figure III-8. Evaluation of the ICL formation using Ce6 and different DMSO concentrations.  
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III.2.2. TriPyCOOH as a photosensitiser 
TriPyCOOH porphyrin was kindly provided by Dr. Tomé (Universidade de Lisboa), in the 
context of a collaboration established within the SO2S ITN. This porphyrin has been 
successfully used against Gram-positive bacteria in wastewater treatment, (13) against 
herpes simplex virus type 1 (HSV-1) (14) and for PDT. (15) The presence of only one carboxylic 
acid functionality should allow for a selective and directed attachment of the molecule to an 
ODN. Since porphyrin absorbance in the red region is rather low, we first set out to evaluate 
whether red or white light was the most suitable for crosslinking generation (figure III-9). 
Solutions of the duplex were prepared at 20 M and the porphyrin was added just before 
irradiation at 5 or 10 M, that is, keeping a 4:1 or 2:1 duplex/porphyrin ratio respectively. 
HPLC analysis of the samples showed that, surprisingly, the use of red light led to higher 
crosslinking yields, since the use of white light resulted in a lower yield of the crosslinked 
adduct that also started to decay after 30-60 min irradiation. On the other hand, when red 
light was used, ICL formation proceeded until 3-4 hours before a decrease in yield was 
observed.  
 
Figure III-9. Evaluation of red and white light irradiation using TriPyCOOH as PS. Experiments at 4:1 
duplex/TriPyCOOH ratio contain 20 M concentration of the duplex and 5 M concentration of TriPyCOOH; 2:1 
duplex/TriPyCOOH ratio contain 20 M concentration of the duplex and 10 M concentration of TriPyCOOH. Yields 
were calculated by dividing the peak area of the cross-linked product in the chromatogram by the peak area of 
the limiting single stranded oligonucleotide in the initial HPLC chromatogram, both corrected for their extinction 
factor  
Subsequently, the crosslink generation using TriPyCOOH and red light was evaluated. As 
when using Ce6, the duplex was used at 2 or 20 M concentration and TriPyCOOH was used 
at either 2 M concentration, in the case of 2 M of the duplex, or 5 or 10 M when 20 M 
of the duplex was used. RP HPLC and PAGE analysis will be shown here for the experiment 
showing the highest crosslinking yield. 
44 
 
Only small differences were found among the three systems and after 3 hours the same yield 
was obtained. Further irradiation of the solution where 10 M was used resulted in a slow 
decrease of the crosslinking yield and the highest yield was obtained when using 5 M after 
4 hours (47%) and PAGE analysis confirmed the formation of the crosslink as a slower 
migrating band can be observed (figure III-10b and c).  
  
Figure III-10. ICL formation using TriPyCOOH as PS. a) Summary of the crosslinking yields at 3 different ratios. b) 
RP HPLC analysis of the ICL experiment where [duplex]=20 M  and [TriPyCOOH]=5 M (XBridge column, linear 
gradient of 0-20% ACN in 30 min);  c) PAGE analysis of the same experiment (20% polyacrylamide, 1x TBE buffer, 
GelRedTM used for staining).  
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III.2.3. TT1 as a photosensitiser 
The third PS evaluated was TT1 phthalocyanine which was kindly provided by Prof. Torres 
(Universidad Autónoma de Madrid), also as part of a collaboration within the SO2S ITN. TT1 
was originally designed as a photosensitizer for Dye-Sensitized Solar Cells as its bulky, 
hydrophobic substituents result in an improved solubility in organic solvents and allow to 
avoid aggregation which is so common among phthalocyanines due to their extended 
aromatic system. (16) Since aggregation of this hydrophobic compounds would especially 
occur in aqueous conditions, during the evaluation of TT1 in solution higher amounts of 
DMSO were used, up to 20%. However, even the addition of DMSO did not seem to prevent 
aggregation as the crosslink formation was rather inefficient. Phthalocyanine aggregation 
results in quenching of the excited states of the PS which interferes with 1O2 generation, even 
though light absorption in the red region is particularly strong for these compounds.  
Again, TT1 was evaluated at different duplex/PS ratios. When the duplex concentration was 
20 M, TT1 was added at 5, 10 and 20 M, at a final DMSO concentration of 5, 10 and 20% 
respectively. When the duplex concentration was 2 M, TT1 was added in a 1:1 ratio and at 
20% DMSO concentration. A summary of the crosslinking yields can be found in figure III-11. 
In this case, there is a direct correlation between the PS concentration and the ICL formation, 
probably due to the fact that most of the phthalocyanine is quenched leading to an inefficient 
1O2 generation and addition of more PS has a beneficial effect on the ICL formation.  
However, it is worth noting that the use of higher amounts of DMSO may have an influence 
on the duplex stability. For this reason, the melting temperatures (Tm) of the duplexes in the 
presence of 5, 10 and 20% DMSO were evaluated. As can be observed in table III-3, there was 
almost no influence up to 10% DMSO. Only when the concentration was increased up to 20% 
some destabilisation was observed but even in this case, most of the duplex was formed at 
the temperature at which the crosslinking experiments are performed (25ºC).  
Table III-3. Tm of the FON1-ON1 duplex in the presence of different DMSO concentrations. Measurements were 
carried out at 1 μM duplex concentration in a 100 mM NaCl and 10 mM phosphate buffer following the absorption 
at  λ = 260 nm..  
DMSO (%) Tm (ºC) Tm with 0% DMSO 
0 36.7 0 
5 35.8 -0.9 
10 37.0 0.3 
20 32.2 -4.5 
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Figure III-11. ICL formation using TT1 as PS. a) Summary of the crosslinking yields at 3 different ratios and 
concentrations. b) RP HPLC analysis of the ICL experiment where [duplex] = [TT1]= 20 M and (Aeris column, linear 
gradient of 0-20% ACN in 30 min);  c) PAGE analysis of the same experiment (20% polyacrylamide, 1x TBE buffer, 
GelRedTM used for staining).  
 
III.3. Evaluation of a non-nucleobase furan building block. 
Once the optimised conditions for ICL generation for each PS were established using the 
FON1/ON1 duplex, we decided to evaluated the second furan containing ODN, FON2, hybridised 
to its complementary strand ON1 (table III-4). This building block showed a high yielding ICL 
formation when using MB for 1O2 generation (1,17). It is important to note that the use of this 
furan building block spontaneously proceeds to the aromatised adduct (figure III-12) and it is 
observed as a single signal by RP HPLC, contrary to the previous furan building block evaluated.  
Table III-4. Furan modified strand (FON2) and its complementray sequence (ON1) used during the following 
crosslinking experiements. 
Name Sequence 
FON2 5’ - CTG ACG G2G TGC - 3’ 
ON1 3’ - GAC TGC CCC ACG – 5’ 
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Figure III-12. Formation of the aromatic crosslinked adduct that results when FON2 is used for ICL with the 
complementary strand ON1. 
As in the previous experiments, the two ODNs were mixed together and allowed to hybridise in 
a phosphate buffer solution. Then, the PS of choice was added just before irradiation and 
samples were taken at different times and analysed by RP HPLC and PAGE.  
When Ce6 was used as a PS, the duplex and the dye were added at 2 M concentration as it was 
shown before to induce the highest ICL formation. However, under these conditions the 
crosslink yield was much lower, only up to 19%, compared to the 52% obtained before (figure 
II-13b).  
In the case of TriPyCOOH, the used of this PS under the previously optimised conditions (20 M 
concentration of the duplex, 5 M concentration of TriPyCOOH) did not produce a crosslink that 
can be easily observed in the HPLC chromatogram (figure III-14a). However, the formation of 
the crosslink is confirmed by PAGE (figure III-14b) but crosslinking yields could not be estimated. 
The use of a higher (10 M) concentration and white light were also attempted, but under none 
of these conditions the formation of the crosslinked adduct was observed by RP HPLC (the 
original chromatograms are included in chapter X) 
Finally, the use of TT1 at 1:1 duplex/PS ratio (2M) in the presence of 20% DMSO, resulted in 
crosslink formation at slightly lower yields compared to when FON1 was used (Figure III-15b). A 
comparison between the crosslink yields using the two building blocks is shown in table III-5. 
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Figure III-13. ICL formation using Ce6 as PS and FON2/ON1 as duplex where [duplex]=[Ce6]=2 M. a) Evolution of the 
crosslinking yield over time. b) RP HPLC analysis of the ICL experiment (XBridge column, linear gradient of 0-20% ACN 
in 30 min); c) PAGE analysis of the same experiment (20% polyacrylamide, 1x TBE buffer, GelRedTM used for staining). 
 
Figure III-14. ICL formation using TriPyCOOH as PS and FON2/ON1 as duplex where [duplex]=20 M  and 
[TriPyCOOH]=5 M. a) RP HPLC analysis of the ICL experiment (XBridge column, linear gradient of 0-20% ACN in 30 
min);  b) PAGE analysis of the same experiment (20% polyacrylamide, 1x TBE buffer, GelRedTM used for staining).  
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Figure III-15. ICL formation using TT1 as PS and FON2/ON1 as duplex where [duplex] = [TT1]= 2 M. a) Evolution of 
the crosslinking yield over time. b) RP HPLC analysis of the ICL experiment and (Aeris column, linear gradient of 0-20% 
ACN in 30 min);  c) PAGE analysis of the same experiment (20% polyacrylamide, 1x TBE buffer, GelRedTM used for 
staining). 
 
Table III-5. Comparison between the ICL yields using the two furan ODNs.  
PS ICL yield using FON2 (%) ICL yield using FON1 (%) 
Ce6 19 52 
TriPyCOOH - 47 
TT1 12 17 
 
III.4. Crosslinking using porphyrin containing nanoparticles. 
These NPs were available to us through a collaboration with the University of Aveiro in the 
context of the European ITN SO2S. The attachment of porphyrins to magnetic silica NPs has been 
used for wastewater treatment since the presence of the Fe3O4 core allows the recovery of the 
NPs after the water treatment allowing the recycling of these compounds. (18) In the present 
study, glucose-decorated porphyrin conjugated NPs (figure III-16), synthesised by Lucía 
Fernández, were used for crosslinking generation.  
50 
 
 
Figure III-16. Structure of NPs used for ICL generation. They consist of a magnetic core coated with a silica shell that is 
functionalised with the porphyrins.  
Since porphyrins are the only active element in the NP, the concentration in this case refers to 
the porphyrin content. An estimation of the porphyrin content was calculated by the difference 
between the amount of porphyrin used during the synthesis of the functionalised NPs and the 
remaining dye at the end of the reaction, determined by UV-Vis absorbance. The crosslink 
experiments were carried out using the FON1-ON1 duplex at a 20 M concentration and the 
NPs were added at 10 M concentration just before irradiation. Under these conditions, red and 
white light irradiation was evaluated (figure III-17a), and samples were taken at different times 
and subsequently analysed by RP HPLC and PAGE.  
The use of white light resulted in this case in better crosslinking yields when compared to the 
red light irradiation, up to 28% as determined by RP HPLC (figure III-17b), and the formation of 
the ICL could be confirmed by PAGE analysis (figure III-17c).  
It can be concluded from these experiments that PS-equipped NPs are suitable 1O2 generators 
for inducing ICL formation.  
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Figure III-17. ICL formation using PS-equipped magnetic silica NPs. a) Overview of the crosslinking yields in function of 
time of irradiation using 2 different light types, red and white. b) RP HPLC analysis  of the ICL experiment where 
[duplex]=20 M and [NPs]= 10 M and white light (XBridge column, linear gradient of 0-20% ACN in 30 min); c) PAGE 
analysis of the same experiment (20% polyacrylamide, 1x TBE buffer, GelRedTM used for staining). 
 
III.5. Conclusions 
During this chapter, an extensive study of the three PSs of choice was carried out under a variety 
of reaction conditions and for each system a set of optimal parameters was defined.  
Among the PSs tested, Ce6 performed the best for inducing ICL, closely followed by TriPyCOOH. 
On the other hand, TT1 phthalocyanine seemed to suffer from its low solubility in aqueous 
conditions that would induce aggregation among the dyes.  
Moreover, an alternative furan building block was used for comparison, showing lower 
crosslinking yields than the uridine based building block 
Finally, an alternative 1O2 generation system was evaluated consisting of magnetic silica NPs 
decorated with porphyrins. The NPs were tested in a crosslinking context and they were able to 
successfully induce ICL formation. These NPs seem to be promising candidates for ICL generation 
compared under white light irradiation since they showed a crosslink formation up to 28% 
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already after one hour, whilst in the case of the free porphyrins only yields up to 15% were 
observed after this irradiation time. Further investigation of this system is worthy but was not 
undertaken here due to lack of time.  
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Chapter IV. 
Photosensitiser conjugated oligonucleotides. 
Synthesis, 1O2 generation and crosslinking 
evaluation.  
The main part of this work was published in: 
Porphyrin-based photosensitizers and their DNA conjugates for singlet oxygen 
induced nucleic acid interstrand crosslinking, Org. Biomol. Chem., 2017 
 
 
In this chapter, the PSs evaluated in Chapter 3 are conjugated to the 
ODN sequences complementary to the furan containing ODNs. 
Conjugation of the PSs to the ODNs results in the local generation of 
1O2, minimising off-target reactions and avoiding the need to add 
organic solvents for solubility. Then, the 1O2 generation of these 
conjugates is evaluated and a comparative study of the different 
probes for crosslink formation is carried out.  
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IV.1.  Photosensitiser conjugated nucleic acids 
Conjugation of photosensitisers to nucleic acids has been studied in various contexts, ranging 
from therapeutic applications to structural studies. Ce6 has been used in conjugation with 
aptamers for directed PDT and with antisense oligonucleotides to achieve a combined PDT (1,2) 
and splicing switching effect for cancer treatment. (3) In a different therapeutic approach, PS-
induced cleavage has been reported using cationic porphyrins (4) or napthoquinones (5) or more 
recently the use of photosensitiser conjugated peptide nucleic acids (PNA) derivatised with rose 
bengal or 5-carboxytetramethylrhodamine (TAMRA). (6,7) 
The study of the structure and dynamics of nucleic acids using porphyrin conjugated 
oligonucleotides has been reported in detail by the group of Berova (8–11) and Stulz. (12–14) 
Introduction of the photosensitisers has been carried out through various approaches but the 
introduction of amino groups is the most widely used due to the availability of commercially 
available modifiers that allow in terminal or in internal modification and also the feasibility of 
the conjugation reaction. (1,3,4,7) However, other approaches have been explored e.g. previous 
conjugation of the PS to a nucleoside for later introduction into the growing chain, (8,15,16) 
terminal modification via the H-phosphonate approach (17) or via postsynthetic cycloaddition 
reaction using a furan containing oligonucleotide, directly inspired by the methodology 
developed in the OBCR group. (18)  
IV.2.  Synthesis of amino modified ODNs. 
Different amino modified ODNs were synthesised to study the behaviour of the PSs of interest 
when conjugated to an ODN. First, 5’-amino modified ODNs complementary to the furan 
containing sequences used in the previous chapter (FON1 and FON2) were either purchased or 
synthesised and kept on the CPG for conjugations on solid support. Two different 5’-amino 
modifiers were used, differing in the linker length between the amino group (three or six carbon 
atoms) and the phosphate group of the last nucleobase (figure IV-1). The different sequences 
are presented in table IV-1.  
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Figure IV-1. a) Schematic representation of the furan ODN/amino or PS-ODN duplexes; b) Amino modifiers and furan 
building block used for the ODN synthesis. 
Table IV-1. Summary of the amino and furan modified sequences. All sequences were in home synthesised except ON3. 
ON2 was purchased as the free ODN but synthesised for on solid support conjugations.   
Name Sequence (5’-3’) Modification 
ON2 X-GCA CCC CGT CAG X= Am6 
ON3 X-GCA CCC CGT CAG X= Am3 
FON1 CTG ACG G1G TGC 
 
 
FON2 CTG ACG G2G TGC 
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IV.3.  Synthesis of PS conjugated ODNs. 
Conjugation between the different PSs and the ODNs was achieved via amide bond formation 
between the amine functionality of the ODNs and the carboxylic acid of the dyes. First, the ODN 
of choice was ON2, functionalised with the C6 linker at the 5’ end. For each PS a different 
activation method of the carboxylic acid needed to be used, as described below. 
IV.3.1 Ce6 conjugated ODN 
For Ce6, DCC/NHS activation was used. First, the chlorin was dissolved in DMF and DCC and 
NHS were added and this mixture was stirred in the darkness at 0ºC for 1 hour under Ar 
atmosphere. Then, ON2 was added dissolved in NaHCO3 buffer solution (pH 8.3, to minimise 
the hydrolysis of the NHS ester). The reaction mixture was stirred overnight in the darkness, 
to prevent undesired 1O2 generation at this point. Subsequently, part of the unreactive Ce6 
was removed by precipitation before RP HPLC purification. Conjugate PON1 was obtained 
in 30% yield.  
 
Figure IV-2. Synthesis of the Ce6 conjugated ODN, PON1. 
During RP HPLC purification, the conjugate was identified by its characteristic UV-Vis 
absorbance, featuring maximums at 260 nm, 400 nm and 650 nm (figure IV-3 and IV-4) and 
by mass analysis using MALDI-TOF. After purification, the absorption coefficients 
characteristic of the Ce6 moiety were calculated based on the absorption at 400 nm and 
the concentration of the conjugate as determined by the absorption at 260 nm, as 
presented in table IV-2. 
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Figure IV-3. RP HPLC chromatogram of PON1 a) before purification b) after purification (0-50% ACN in 15 min, 
Discovery BIO Wide Pore C5 column, top: 260 nm and bottom: 400 nm).  
 
Figure IV-4. UV-Vis spectrum of PON1. 
Table IV-2. PON1 absorption coefficients. 
 PON1 
Wavelength (nm) 410 645 
 (L·mol-1·cm-1) 1.66·105 2.2·104 
 
IV.3.2 TriPyCOOH conjugated ODN 
In the case of the porphyrin, the NHS activated ester was also provided by the group of Dr. 
Tomé. The conjugation was carried out by dissolving the porphyrin in DMSO and adding 
ON2 in NaHCO3 and allowing the reaction mixture to stir overnight in the darkness under 
Ar atmosphere. The unreacted TryPyCOONHS was removed by precipitation before RP 
HPLC purification (figure IV-6). The obtained PON2 conjugate (17% yield) was analysed by 
MALDI-TOF and UV-Vis (figure IV-7). The absorption coefficients were calculated and are 
presented in table IV-3. 
 
6 
 
 
Figure IV-5. Synthesis of the TriPyCOOH conjugate, PON2.  
 
Figure IV-6. RP HPLC chromatogram of PON2 a) before purification b) after purification (0-50% ACN in 15 min, 
Discovery BIO Wide Pore C5 column top: 260 nm and bottom: 420 nm). 
 
Figure IV-7. UV-Vis spectrum of PON2. 
Table IV-3. PON2 absorption coefficients. 
 PON2 
Wavelength (nm) 425 520 555 590 650 
 (L·mol-1·cm-1) 1.82·105 1.5·104 7·103 6·103 3·103 
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IV.3.3 TT1 conjugated ODN 
Conjugation between TT1 phthalocyanine and ON2 was troublesome, probably due to the 
high insolubility of this dye in the aqueous conditions required to solubilise the ODN. The 
NHS activated ester of TT1 was synthesised and several attempts were carried out in 
solvent mixtures of DMSO or DMF with NaHCO3, NH4HCO3 or Tris, at different ratios, but 
the conjugation was unsuccessful in all cases.  
Table IV-4.Summary of conditions screened for the TT1 conjugation to ON2. 
Organic solvent (org) DMF DMF DMSO DMSO DMF DMSO 
Buffer (buf) NH4HCO3 Tris NH4HCO3 Tris NH4HCO3 NaHCO3 
Ratio org/buf 20:80 20:80 20:80 20:80 80:20 80:20 
  
We rationalised that the use of a water-free solvent system would favour a conjugation 
where one of the partners is highly insoluble in aqueous conditions. For this, a new ODN 
needed to be synthesised and, in this case, kept attached to the solid support selectively 
deprotecting the 5’-amino group. After the conjugation using HBTU/DIPEA activation of TT1, 
following a previously reported modified procedure, (19) the ODN was deprotected and 
cleaved from the solid support by NH4OH treatment at 55ºC overnight and the obtained 
conjugate PON3 was purified by RP HPLC (figure IV-9) and characterised by UV-Vis (figure 
IV-10 and table IV-5) and MALDI-TOF.  
 
Figure IV-8. Synthesis of the TT1 conjugate, PON3. 
It is important to note that this conjugation on solid support does not allow monitoring of 
the reaction, and reaction times had to be estimated. Moreover, even under these 
conditions low yields were obtained so we carried out an additional optimisation of the 
reaction. For this purpose, another batch of ON2 was synthesised, this time on a CPG with 
bigger pores (1000 Å rather than 500 Å) to facilitate the reaction on the solid support. 
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Besides, TT1 was premixed with HBTU and DIPEA in DMF and added portion wise over 2 
hours. Following this procedure, yields up to 20% were obtained after RP HPLC purification. 
As can be observed in figure IV-9, PON3 appears as two different signals in the HPLC 
chromatogram. This is explained by the fact that TT1 is actually a regioisomeric mixture and 
upon conjugation to ON2 results in a mixture of different species of the PS conjugated ODN. 
The two main signals were separately isolated and characterized and were found to have 
the same mass and spectroscopic properties. Therefore, the mixture of conjugates was 
further used as if one single compound for the crosslinking experiments. 
 
Figure IV-9. RP HPLC chromatogram of PON3 a) before purification and b) after purification (0-80% ACN in 15 
min, Discovery BIO Wide Pore C5 column, top: 260 nm and bottom: 680 nm).  
 
Figure IV-10. UV-Vis spectrum of PON3. 
Table IV-5. PON3 absorption coefficients.  
 PON3 
Wavelength (nm) 350 685 695 
 (L·mol-1·cm-1) 5.9·104 1.17·105 1.20·105 
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IV.4.  Singlet oxygen generation of the PS conjugated ODN.  
Since the synthesised PS conjugated ODNs will be evaluated for ICL formation using 1O2 as 
oxidant, it is important to determine their 1O2 generation capacities under the conditions that 
will be used during the crosslinking experiments.  
Determination of 1O2 generation can be done via several methods, e.g. by detecting its 
phosphorescence at 1270 nm or using a chemical trap that reacts with 1O2, producing a 
structural change that can be easily measured, for example, a decrease in the reporter 
absorption. Here, we use the chemical trap method for its simplicity and the possibility of using 
very small amounts of the PS-ODN conjugates.  
As a reporter, 9,10-anthracenediyl-bis(methylene)dimalonic acid (ABDA) was used. ABDA is 
soluble in PBS buffer and, by following the decrease of its absorbance at 350-415 nm (over this 
range three absorption maxima can be observed, figure IV-12) upon irradiation in the presence 
of the PS conjugated ODNs, it is possible to compare the 1O2 generation of the different 
conjugates.  
 
Figure IV-11. Reaction between ABDA and 1O2 resulting in the quenching of the absorbance of ABDA at 350-415 nm. 
Each conjugate was used at 2 M concentration in the presence of 100 M ABDA in a phosphate 
buffer solution. Upon irradiation with red light, samples were taken at different times and the 
UV-Vis absorption was determined (figure IV-12). For PON1-3 the relative decrease in 
absorbance was determined at 380 nm and is presented in figure IV-12d. 
The 1O2 generation of the PS conjugated ODNs was PON3 > PON1 > PON2, in direct correlation 
with their light absorption in the red region. However, it is important to note that a higher 1O2 
generation does not necessarily means a higher crosslinking yield since we have observed that 
an excessive production of the oxidising agent leads to more degradation decreasing the overall 
ICL yield.  
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Figure IV-12. Singlet oxygen generation of a) PON1, b) PON2 , c) PON3 and d) comparison of the conjugates by 
following the decrease in the absorption of ABDA at 380nm. 
 
IV.5.  Crosslink evaluation using the PS conjugated ODNs. 
With the PS conjugated ODNs in hands and having determined their abilities to produce 1O2 in 
aqueous conditions under red light irradiation, we set out to evaluate the suitability of each 
conjugate for ICL formation with a furan modified complementary strand. During this first 
evaluation, FON1 was used in combination with PON1-PON3 (table IV-6). 
Table IV-6. Summary of modified sequences for ICL evaluation.  
ODN Sequence (5’-3’) Modification 
FON1 
 
CTG ACG G1G TGC 
   
PON1 PS-Am6- GCA CCC CGT CAG PS = Ce6 
PON2 PS-Am6- GCA CCC CGT CAG PS = TriPyCOOH 
PON3 PS-Am6- GCA CCC CGT CAG P3 = TT1 
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The duplex was solubilised in phosphate buffer solution at 2 M concentration, to minimise 
interaction between 1O2 generated by one duplex and a neighbouring strand that would result 
from the use of higher concentrations. Irradiation times were optimised for each conjugate since 
too long irradiation results in a decrease of the crosslinking yield after a maximum is obtained. 
For all the conjugates, the time needed to achieve the highest ICL yields is much lower compared 
to the ICL experiments where the PSs were used in solution.  
IV.5.1  Ce6 conjugate (PON1) 
The PON1 conjugate was added together with FON1 in a buffer solution at a final 
concentration of 2 M and the solution was irradiated using red light for 15 min, taking 
samples at different times. RP HPLC analysis showed that maximum ICL formation occurred 
after 3 min irradiation (34% yield), decreasing after this point (figure IV-13a and b). It is 
worth noting that in this case the two signals that were observed in previous crosslinking 
experiments using FON1, and which were assigned to be the crosslinked adduct, are not 
observed now. Instead, only one peak appears which suggests that either the two 
diastereomers are not formed or distinguished in this case, or that one of the signal overlaps 
with PON3, which would result in yield underestimation. PAGE analysis confirmed the 
formation of the crosslinked adduct that corresponds to the slower migrating band observed 
(figure IV-13c). In this case, GelGreenTM was used for staining since GelRedTM emits in the 
region of the electromagnetic spectrum where the chlorin absorbs, preventing a clear 
visualisation of the different bands.  
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Figure IV-13. ICL formation using the PON1/FON1 duplex. a) Evolution of the ICL yields during irradiation. b) RP 
HPLC analysis of the ICL experiment (Discovery C5 column, linear gradient of 0-50% ACN in 15 min). c) PAGE 
analysis of the same experiment visualized using GelGreenTM (20% polyacrylamide, 1x TBE buffer).  
 
IV.5.2 TriPyCOOH conjugate (PON2) 
As in the previous case, PON2 was allowed to hybridise with FON1 in phosphate buffer 
solution and the solution was irradiated using red light for 5 min. However, in this case no 
ICL formation was observed neither by RP HPLC or PAGE analysis. Rather, oxidation of FON1 
was followed by degradation thereof.  
 
Figure IV-14. No ICL formation occurred when using the PON2/FON1 duplex. a) RP HPLC analysis of the ICL 
experiment (Discovery C5 column, linear gradient of 0-50% ACN in 15 min).  b) PAGE analysis of the same 
experiment visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
One possible explanation for this could be the low 1O2 generation as described in the 
previous section, due to the porphyrin low absorption of red light. For this reason, we 
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decided to evaluate other TriPyCOOH conjugated ODNs where the porphyrin will be in 
closer proximity to the furan on the opposite strand. If the lack of crosslink generation is 
related to an insufficient 1O2 generation, placing the PS closer to the furan may help to 
ensure a higher local 1O2 concentration at the reaction site. For this purpose, a 5’-amino 
modified ODN with a shorter (three carbon atoms instead of six) linker was used for 
conjugated to TriPyCOOH. 
 
IV.5.2.1.   Use of a shorter linker 
For the synthesis of the porphyrin conjugate with a shorter linker, ON3 was reacted with 
TriPyCOONHS in a DMSO/NaHCO3 buffer solution following the same procedure as 
described in section IV-3.2. The obtained conjugate, PON4, was hybridised with FON1 
at 2 M concentration and irradiated for 5 min using red light. The samples were 
analysed by RP HPLC and PAGE.  
Table IV-7. Sequences used during the evaluation of TriPyCOOH as PS using shorter linker for 
conjugation to the ODN. 
ODN Sequence (5’-3’) Modification 
FON1 CTG ACG G1G TGC 
 
 
PON4 PS-Am3- GCA CCC CGT CAG PS = TriPyCOOH 
 
Although RP HPLC analysis seemed to show the appearance of a new signal next to the 
signal corresponding to PON4 and FON1 was consumed after 5 min irradiation (figureIV-
15a, bottom chromatogram) ICL formation could not be confirmed by PAGE (figure IV-
15b). 
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Figure IV-15. No ICL formation occurred when using PON4/FON1 duplex. a) RP HPLC analysis of the ICL 
experiment (Discovery C5 column, linear gradient of 0-50% ACN in 15 min).  b) PAGE analysis of the same 
experiment visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
 
IV.5.3 TT1 conjugate (PON3) 
Moving on to the last PS, the PON3 conjugate was evaluated in combination with FON1. ICL 
formation was observed already after one minute irradiation, decreasing after this moment 
(figure IV-16a). HPLC analysis showed the appearance of two new signals next to that of 
PON3, reaching a maximum estimated yield of 12% (figure IV-16a and b). PAGE analysis 
confirmed the crosslink formation showing that several adducts were obtained, which is 
not surprising taking into account that PON3 was used as a mixture of different species 
resulting from the regioisomeric nature of TT1.  
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Figure IV-16. ICL formation using the PON3/FON1 duplex. a) Evolution of the ICL yields during irradiation. b) RP HPLC 
analysis of the ICL experiment (Discovery C5 column, linear gradient of 0-80% ACN in 15 min). c) Zoom-in of the 
chromatogram region where the formation of the ICL species takes place, overlapping the PON3 regioisomers d) PAGE 
analysis of the same experiment visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
 
IV.6.  Melting temperature analysis of the duplexes. 
The lack of crosslink formation when using the conjugates containing TriPyCOOH led us to study 
the duplex stability by determining the melting temperatures (Tm). Moreover, we expected to 
observe a correlation between the 1O2 generation abilities of the PS-ODN conjugates and the ICL 
formation, which was not the case. PON3, which had a more efficient 1O2 generation, only 
showed a 12% crosslinking yield in combination with FON1, compared to the 34% crosslinking 
yield obtained using PON1, which had a more mediocre 1O2 generation. We expected that Tm 
determination would shed some light on this results.  
The different 5’ modified conjugates (PON1-PON3) were hybridised with FON1 at 1 M 
concentration in phosphate buffer solution and the Tm values were determined and compared 
to the duplex where no PS is conjugated, as presented in table IV-9. 
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Table IV-8. Summary of the Tm values for 5’ modified Ps conjugated ODNs and FON1.  
ODN 1 ODN 2 Tm (ºC) Tm with the unmodified duplex 
FON1 ON1 35.8 0 
FON1 PON1 Tm = 38.3; Ta = 34.2 Tm= 2.5; Ta = -1.6 
FON1 PON2 29.2 -6.6 
FON1 PON3 33.5 -2.3 
Ta: annealing temperature. 
As can be inferred from these results, the duplex PON2/FON1 is highly destabilised, which, in 
combination with the poor 1O2 generation would explain the inability to induce a crosslink. 
Furthermore, the slight destabilisation of the PON3/FON1 duplex could explain the rather low 
ICL formation in spite of the good 1O2 generation of the PS-ODN conjugate. Finally, in the case 
of PON1 the Ta and Tm values were rather different showing a stabilisation of the PON1/FON1 
duplex once that is formed. This, together with a sufficient 1O2 generation would account for 
this being the system that showed the highest ICL formation.  
IV.7.  ICL evaluation at lower temperature. 
In view of the Tm results, we rationalised that lower temperatures may assist the ICL formation 
by performing the experiment in a context where the duplex is formed to a higher extent 
compared to 25ºC. We again used PON1-PON3 conjugates in combination with FON1 at 2 M 
concentration but the experiments were now carried out at 10ºC instead of 25ºC. However, 
even at lower temperature PON2 was not able to induce ICL formation and PON1 and PON3 
performed in a similar manner, with slightly lower crosslinking yields (table IV-9). 
Table IV-9. Summary of the yields obtain at two different temperatures using FON1 and PON1-3. 
PS-ODN conjugate ICL yield at 10ºC ICL yield at 25ºC 
PON1 27% 34% 
PON2 No ICL No ICL 
PON3 8% 12% 
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IV.8.  Crosslinking using a non-nucleobase furan building block. 
Conjugates PON1, PON3 and PON4 were also evaluated in combination with FON2, containing 
the phenyl-based furan building block, as presented in table IV-10. 
Table IV-10. Sequences used during the evaluation of FON2 with the PS-ODN conjugates. 
ODN Sequence (5’-3’) Modification 
FON2 
 
CTG ACG G2G TGC 
 
 
PON1 PS-Am6- GCA CCC CGT CAG PS = Ce6 
PON4 PS-Am6- GCA CCC CGT CAG PS = TriPyCOOH  
PON3 PS-Am3- GCA CCC CGT CAG PS = TT1 
 
As in the previous experiments the duplexes were used at 2 M concentration and irradiated 
using red light. Analysis by RP HPLC and PAGE showed similar results to the ones obtained when 
using the ODN containing the uridine-based furan building block FON1. The TriPyCOOH 
conjugated ODN, in this case with a shorter linker, PON4, did not showed any ICL formation 
(figure IV-18) whereas PON1 and PON3 reached somewhat lower crosslinking yields (PON1: 22% 
vs 34%, and PON3 9% vs 12%) but differences were not as striking as when the two building 
blocks were compared using the PSs in solution in the previous chapter.  
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Figure IV-17. ICL formation using PON1/FON2 duplex. a) Evolution of the ICL yields during irradiation. b) RP HPLC 
analysis of the ICL experiment (Discovery C5 column, linear gradient of 0-50% ACN in 15 min). b) PAGE analysis of the 
same experiment visualized using GelGreenTM (20% polyacrylamide, 1x TBE buffer). 
 
 
Figure IV-18. No ICL formation occurred when using PON4/FON2 duplex. a) RP HPLC analysis of the ICL experiment 
(Discovery C5 column, linear gradient of 0-50% ACN in 15 min).  b) PAGE analysis of the same experiment visualized 
using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
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Figure IV-19. ICL formation using PON3/FON2 duplex. a) Evolution of the ICL yields during irradiation. b) RP HPLC 
analysis of the ICL experiment (Discovery C5 column, linear gradient of 0-80% ACN in 15 min). c) Zoom-in of the 
chromatogram region where the formation of the ICL species takes place, overlapping the PON3 regioisomers d) PAGE 
analysis of the same experiment visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
 
IV.9. Melting temperature analysis of the duplexes using FON2. 
The duplexes formed by FON2 and the different PS conjugated ODN were also evaluated for 
their thermal stability as presented in table IV-11. A similar trend to the FON1 duplexes is 
observed: the biggest destabilisation is observed when using PON2 and PON3 duplex also shows 
some destabilisation. However, in this case, PON1 does not show any stabilisation.  
Table IV-11. Summary of the Tm values for 5’ modified Ps conjugated ODNs and FON2. 
ODN 1 ODN 2 Tm (ºC) Tm with the unmodified duplex 
FON2 ON1 Tm = 52.2; Ta = 47.7 - 
FON2 PON1 46.6 -3.4 
FON2 PON2 Tm = 37.2; Ta = 34.5 Tm= -15 ; Ta =-13.2 
FON2 PON3 45.4 -4.6 
 
IV.10. Distance evaluation using a non-nucleobase building block  
In view of the similar crosslinking yields when using FON2 and the PS conjugated ODNs, a further 
attempt was carried out to achieve ICL formation using the TriPyCOOH conjugates. For this 
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purpose, a new sequence was designed to containing several T nucleobases to introduce internal 
modifications and for each ODN, one modified T, T*, was introduced at different positions. The 
amino modification is attached to the nucleobase via a six carbon linker and introduction was 
achieved via automated synthesis in an identical manner as with non-modified nucleobases, as 
described in chapter 3. For this sequences, the complementary furan sequence was synthesised, 
using the phenyl-based furan building block 2 due to availability. Duplex formation between 
FON3 and ON4-ON7 (table IV-12) results in four different systems that allow screening of the 
influence of the distance between the furan moiety and the PS, introduced through the amino 
modified nucleobase. 
Table IV-12. Summary of the amino and furan modified sequences used for the distance evaluation.  
Name Sequence (5’-3’) Modification 
ON4 GTA CCC TGT CT*G 
 
ON5 GTA CCC TGT* CTG 
ON6 GTA CCC T*GT CTG 
ON7 GT*A CCC TGT CTG 
FON3 CAG ACA G2G TAC 
 
  
 
Four conjugates were synthesised using ON4-ON7 and TriPyCOONHS (figure IV-20) following the 
same conjugation strategy as before (section IV-3.2) and purified by RP HPLC (figure IV-21). 
 
Figure IV-20. Schematic representation of the furan ODN/amino or PS duplexes (4 duplexes are formed in total). 
21 
 
 
Figure IV-21. RP HPLC purification of PON5-PON8 conjugates (for each chromatogram, top: 260nm, bottom: 420nm). 
a) PON5 was purified using an Aeris Wide Pore column (0-10% ACN in 15 min then 10-100% ACN in 15 min; b), c) and 
d) PON6-PON8 were purified using a Discovery BIO Wide Pore C5 (linear gradient 0-50% ACN in 15 min). 
Conjugates PON5-PON7 were hybridised with the newly synthesised FON3 (table IV-13), 
irradiated during 5 min using red light and samples were taken at different times that were 
subsequently analysed by RP HPLC and PAGE. Unfortunately, no ICL formation was observed for 
any of the duplexes (figure IV-23). Surprisingly, whereas for some of the experiments there was 
barely no consumption of the furan ODN (figure IV-23a and c), the closer the PS was introduced 
to the 5’ end the faster reacted away FON3 (figure IV-23e and g), suggesting that 1O2 generation 
is facilitated. However, it cannot be concluded that 1O2 generation is improved by placing the PS 
for closer to the strand termini, since FON3 consumption when using PON5 and PON8 was 
clearly different (figure IV-23a and g) and in both cases TriPyCOOH was introduced one 
nucleobase away from the 3’ and 5’ end respectively. These results seem to indicate that 
position-dependant interactions between the PS and the duplex come into play and that the 5’ 
end is a more suitable position for introducing the PS, in case 1O2 is desired. However, the 
generated 1O2 is in this case not leading to ICL formation but rather to degradation of the furan 
modified strand. 
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Table IV-13. Sequences used during the evaluation of TriPyCOOH introducing the PS as an internal modification. 
Name Sequence (5’-3’) Modification 
PON5 GTA CCC TGT CTPSG 
PS= TriPyCOOH 
PON6 GTA CCC TGTPS CTG 
PON7 GTA CCC TPSGT CTG 
PON8 GTPSA CCC TGT CTG 
FON3 CAG ACA G2G TAC 
 
 
 
 
Figure IV-22. Schematic representation of the duplexes used for the distance evaluation.  
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Figure IV-23. No ICL formation occurred when using PON5-8/FON1 duplexes. a), c), e) and g)  RP HPLC analysis of the 
ICL experiments (Discovery C5 column, linear gradient of 0-50% ACN in 15 min).  b), d), f) and h) PAGE analysis of the 
same experiment visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). a) and b) correspond to PON5/FON3 
duplex; c) and d) to PON6/FON3 duplex; e) and f) to PON7/FON3 duplex; g) and h) to PON8/FON3 duplex.  
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IV.11. Conclusions 
During this chapter, several PS conjugated ODNs were synthesised and evaluated for ICL. The 
synthesis was straightforward in the case of TriPyCOOH porphyrin and chlorin e6 but became 
troublesome when the more hydrophobic TT1 phthalocyanine was used. This last synthesis was 
finally accomplished using on solid phase conjugation.  
Evaluation of crosslink formation showed that the most effective PS-ODN conjugate was the 
ODN modified with Ce6, in agreement with the results reported in the previous chapter where 
the PSs were used in solution.  
Unfortunately, no TriPyCOOH conjugate was able to induce ICL formation, even when the PS 
was placed closer to the furan moiety by the use of a shorter linker or internal modification. This 
PS seems to induce a large duplex destabilisation which in turn prevents crosslinking formation.  
In the case of TT1, in spite of showing good 1O2 generation when conjugated to the ODN, a lower 
ICL formation was observed, probably due to a slight destabilisation of the duplex.  
Finally, the system versatility was tested changing parameters such as temperature and the 
furan building block of choice, but only a small influence on the ICL yield was observed.  
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Chapter V. 
Dual modified photosensitiser/furan self-activating 
systems. Synthesis and evaluation of their 
crosslink behaviour.  
 
In this chapter the different PSs will be introduced in a dual modified 
ODN, containing the furan moiety and an amino group for further 
conjugation. Construction of the so called self-activating probes would 
allow targeting unmodified sequences. However, this proved to be 
troublesome and an alternative design was envisioned, where two 
different ODNs, one containing the furan moiety and one containing 
the PS, target a longer complementary sequence. This longer ODN acts 
as a template to bring the two modified probes together.  
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V.1.  Synthesis of dual modified ODNs. 
Design of the dual modified ODNs was carried out based on the results of the previous chapter. 
The amino modifier was situated at the 5’ end since this allows easier synthetic access to PS-
modified strands. The results in chapter 4 when using the internally modified TriPyCOOH 
conjugated ODNs (section IV-10) also showed that the 1O2 generation seems to benefit from the 
PS being placed at the 5’ terminus, at least in the case of the porphyrin. Since furan building 
blocks 1 and 2 (figure V-1) showed similar crosslinking abilities, they were both introduced in 
the double modified sequences.   
  
Figure V-1. Furan building blocks and amino modifier used for the self-activating probe synthesis.  
 
Synthesis of the dual modified sequence was carried out by automated synthesis, including 
introduction of the amino modifier, as described in chapters 3 and 4. The furan 
phosphoramidites were introduced by manual coupling to maximise coupling efficiencies, as 
previously discussed.   
After synthesis, the dual modified sequence containing building block 2, FON5 (table V-1), was 
divided into two batches (figure V-2). The first one was deprotected and cleaved from the CPG 
using NH4OH, the amino group still protected, and purified using C18 cartridges. The second 
batch was kept on the solid support for conjugation of TT1 and the amino group was 
deprotected on column using TCA to allow the selective conjugation. In the case of FON4, the 
scarce availability of building block 1 only allowed for the synthesis of one sequence that was 
cleaved and deprotected and will only be used for conjugation with Ce6, since this PS showed 
the highest ICL formation between the Ce6 conjugated to an ODN and the furan modified ODN 
in the previous chapter.  
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Table V-1. Summary of the sequences used for the self-activating probe evaluation.  
Name Sequence (5’-3’) 
FON4 Am6- CTG ACG G1G TGC 
FON5 Am6- CTG ACG G2G TGC 
ON1 GCA CCC CGT CAG 
 
 
Figure V-2. Schematic representation of a) the dual modified ODN/ON1 duplexes; b) Partitioning of FON5 for the 
different synthetic approaches. 
V.2.  Synthesis of self-activating furan probes. 
V.2.1.  Phenyl-based furan building block. 
Due to the higher availability FON5, conjugation reactions were first attempted between 
this double modified ODN and the three PSs. However, the synthesis and 
characterisation of the different probes was troublesome in all cases.  
V.2.1.1  Conjugation using Ce6 
The strategy using DCC/NHS activation of Ce6, followed by addition of the dual probe in 
NaHCO3 buffer solution, which was successfully used in chapter 4 (section IV.3.1) for the 
synthesis of the Ce6 conjugated ODN, was also attempted here (Figure V-3). However, 
in this case very low conversion was obtained, only enough to attempt characterisation 
and unfortunately, the correct mass could not be found by MALDI-TOF analysis. 
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Figure V-3. a) Synthesis of the self-activating probe using Ce6 and FON5; b) RP HPLC analysis of the reaction. The 
marked peak shows a UV-Vis spectrum with maxima at 260 and 400 nm that would correspond to the conjugate 
(0-50% ACN in 15 min, Discovery BIO Wide Pore C5 column).  
V.2.1.2  Conjugation using TriPyCOOH 
As previously described in section IV.3.2 in chapter 4, the NHS ester of TriPyCOOH 
porphyrin was dissolved in DMSO and the dual modified FON5 was added in NaHCO3 
buffer. In this case, the reaction seemed to proceed and the appearance of a new peak 
was observed by RP HPLC. After purification of this compound, the new species was 
analysed by MALDI-TOF but unfortunately the correct mass was not obtained. 
 
Figure V-4. a) Synthesis of the self-activating probe using Ce6 and FON5; b) RP HPLC analysis of the reaction. The 
marked peak shows a UV-Vis spectrum with maxima at 260 and 420 nm that would correspond to the conjugate 
(0-20% ACN in 30 min, Clarity C18 column).  
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V.2.1.3  Conjugation using TT1. 
In this case, FON5 was used while still attached to the CPG to allow conjugation without 
the use of buffer solutions, based on the optimised conditions in chapter 4 (section 
IV.3.3). The only change was to carry out the reaction at room temperature instead of 
at 55ºC since the higher temperature leads to a lower conversion in this case. After 
cleavage and deprotection using NH4OH, the dual modified conjugate TT1-FON5 was 
purified by RP HPLC and characterised by MALDI TOF. The expected mass was found 
among a complex set of signals that correspond, among others that could not be 
identified, to the species where the furan has been oxidised. However, since it cannot 
be ruled out that the oxidation of the furan happens due to 1O2 generation upon laser 
irradiation during MALDI-TOF analysis, this compound was evaluated for ICL formation.  
 
Figure V-5. a) Synthesis of the self-activating probe using TT1 and FON5; b) RP HPLC analysis of the reaction. The 
marked peak shows a UV-Vis spectrum with maxima at 260 and 680 nm that would correspond to the conjugate 
(0-80% ACN in 15 min, Discovery BIO Wide Pore C5 column).  
 
V.2.2.  Uridine-based furan building block 
Since the highest crosslinking yields in chapter 4 were obtained using the Ce6 conjugated 
ODN, conjugation of this PS was attempted using FON4 as an alternative dual modified ODN 
(Ce6-FON4). The same reaction conditions were used as when FON5 was the ODN of choice 
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but in this case, the reaction proceeds and a new signal was observed by RP HPLC. Analysis 
by MALDI-TOF showed that the furan seems to be already oxidised but since there is the 
possibility that the oxidation happens as a result of the laser irradiation, this Ce6-FON4 was 
tested for ICL formation.  
 
Figure V-6. a) Synthesis of the self-probe using Ce6 and FON4; b) RP HPLC analysis of the reaction. The marked peak 
shows a UV-Vis spectrum with maxima at 260 and 400 nm that would correspond to the conjugate (0-50% ACN in 15 
min, Discovery BIO Wide Pore C5 column). 
 
V.3.  Crosslink evaluation using self-activating probes. 
Self-activating probes Ce6-FON4 and TT1-FON5 were hybridised with the unmodified 
complementary sequence ON1, at 2 M duplex concentration in phosphate buffer solution, 
and irradiated with red light for 5 minutes.  
V.3.1.  Ce6 modified self-activating probe. 
In the case of self-activating probe Ce6-FON4, no ICL formation was observed. Ce6-
FON4 was partially consumed but ON1 remained intact (figure V-8a) and PAGE analysis 
confirmed that no crosslinked adduct was formed (figure V-8b).  
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Figure V-7. No ICL formation was observed using Ce6-FON4. a) RP HPLC analysis of the ICL experiment (Discovery 
C5 column, linear gradient of 0-50% ACN in 15 min). b) PAGE analysis of the same experiment visualized using 
GelGreenTM (20% polyacrylamide, 1x TBE buffer). 
 
V.3.2.  TT1 modified self-activating probe. 
Also when TT-FON5 was used, no crosslink formation was observed either by RP HPLC 
or by PAGE (figure V-9), and as in the previous case, only the self-activating probe was 
consumed.  
 
Figure V-8. No ICL formation was observed using TT1-FON5. a) RP HPLC analysis of the ICL experiment (Discovery C5 
column, linear gradient of 0-80% ACN in 15 min). b) PAGE analysis of the same experiment visualized using GelRedTM 
(20% polyacrylamide, 1x TBE buffer). 
 
V.4.  Evaluation of a self-activating templated system. 
Due to the problematic synthesis and characterisation of the dual modified self-activating 
probes, and their inability to induce ICL, a new strategy was designed in collaboration with Dr. 
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Nathalie De Laet. It was rationalised that the presence of the PS in the same strand as the furan 
moiety may easily lead to 1O2 generation during the handling of the probes that would result in 
the premature oxidation of furan, rendering it unreactive for crosslink formation. Since ICL 
formation was proven successful during the evaluation of PS conjugated ODNs, where the PS 
and the furan moiety are situated in different strands (chapter IV), a system where also the two 
modifications are not placed in the same ODN but the self-activating principle is retained by 
targeting a longer complementary sequence, was designed (figure V-10).  
Previously, this strategy was evaluated using methylene blue or rose bengal conjugated ODNs 
and they were found to be able to induce ICL formation at physiologically relevant 
concentrations (200 nM) towards a 24-mer unmodified ODN. In contrast, the use of such a low 
concentration of the externally added PS, abolished the crosslink formation. 
In this case, sequences FON3 and PON1 (or the unmodified analogue ON1) were hybridised to 
ON9 and evaluated for crosslink formation (table V-2).  
 
Figure V-9. ICL formation using a templated system. a) Using Ce6 in solution and b) using a Ce6 modified ODN (PON1). 
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Table V-2. Summary of the sequences that are used during the crosslinking experiments using the templated system.  
ODN Sequence  Modification 
ON8              3’ - GTC TGT CCC ATG - 5’                                   - 
 
 
 
FON3 
            5’ - CAG ACA G2G TAC - 3’ 
 
 
ON9 3’ - GTC TGT CCC ATG CGT GGG GCA GTC - 5’ - 
ON1                                     5’ - GCA CCC CGT CAG - 3’ - 
PON1                     5’ - PS-Am6 - GCA CCC CGT CAG - 3’ PS = Ce6 
ON10                                       3’ - CGT GGG GCA GTC - 5’ - 
 
First, the melting temperatures of the different duplexes of this three-legged system were 
determined to ensure that the duplexes were not disturbed by the hanging single stranded 
region that exists when only one of the short strands has hybridised the longer target. As 
comparison, FON3 and PON1 were hybridised with their complementary sequences (ON8 and 
ON10 respectively), which correspond to half of ON9. 
Table V-3. Melting temperature values of the duplexes used to evaluate the templated system. 
ODN 1 ODN 2 Tm (ºC) Tm with shorter duplex 
ON8 FON3 37.1 - 
ON9 FON3 65.7 +28.6 
ON10 PON1 58.7 - 
ON9 PON1 67.5 +8.8 
ON9 ON1 66.5 - 
 
The Tm values showed a surprisingly high value that may due to the formation of additional 
tertiary structures.  We reasoned that upon hybridisation of ON9 with both the furan-containing 
FON3 as well as the PS containing strand PON1 as illustrated in  Figure V.10, the system would 
be stable enough to overcome potential tertiary structure formation. This is however difficult to 
ascertain by Tm measurements and we proceeded to evaluate these systems for their 
interstrand crosslinking behaviour. 
The templated system was first evaluated adding Ce6 in solution (200 nM), hybridising ON9 with 
FON3 and the unmodified ON1. The use of lower concentrations allows to evaluate the crosslink 
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formation under conditions resembling a cellular context. Ce6 was added at 200 nM 
concentration to assess whether the crosslink formation is possible under highly dilute 
conditions and also 20 M concentration was used for comparison purposes. Then, the self-
activating system was assessed where the Ce6 modified ODN (PON1) was used instead of ON1. 
V.4.1.  Crosslink formation using a templated system and Ce6 in solution. 
FON3, ON9 and ON1 were hybridised in phosphate buffer solution and Ce6 was added just 
before irradiation using red light. Samples were taken at different times and analysed by RP 
HPLC and PAGE.  
When Ce6 was used at 20 M concentration, ICL formation is observed, reaching a 
maximum of 12% yield after 10 minutes, even if FON3 is almost completely consumed 
(figure V-11b). The formation of the crosslinked adduct was confirmed by PAGE, where a 
slower migrating band appears above the single stranded ODNs (figure V-11c). 
As expected, lowering the Ce6 concentration to a 1:1 ratio with respect to the duplex 
concentration (200 nM) supressed the ICL formation (figure V-12). It is expected that the 
used of Ce6 conjugated ODN would facilitate the crosslink formation by generating 1O2 in 
closer proximity to the furan moiety.  
90 
 
 
Figure V-10. ICL formation using ON1/ON9/FON3 templated system at 200 nM concentration and Ce6 at 20 M 
concentration. a) Evolution of the ICL yield during irradiation. b) RP HPLC analysis of the ICL experiment (XBridge 
column, linear gradient of 0-20% ACN in 30 min). c) PAGE analysis of the same experiment visualized using GelRedTM 
(20% polyacrylamide, 1x TBE buffer). 
 
Figure V-11. No ICL formation was observed when using ON1/ON9/FON3 templated system at 200 nM concentration 
and Ce6 at 200 nM concentration. a) RP HPLC analysis of the ICL experiment (XBridge column, linear gradient of 0-
20% ACN in 30 min). b) PAGE analysis of the same experiment visualized using GelRedTM (20% polyacrylamide, 1x TBE 
buffer). 
 
V.4.2.  Self-activated templated system. 
PON1 was used instead of ON1 for hybridisation with ON9 and FON3 to evaluate whether a 
higher local 1O2 generation assists crosslink formation under highly diluted conditions (200 
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nM). After hybridisation, the reaction mixture was irradiated using red light and samples 
were taken and analysed by RP HPLC and PAGE. Unfortunately, no crosslink formation was 
observed. The RP HPLC chromatogram shows no consumption of the furan containing FON3 
but PON1 disappears. This suggests that 1O2 generation in this system damages the Ce6 
conjugated ODN, PON1, rather than traveling to the furan moiety to induce ICL. PAGE 
analysis was performed using the previous crosslink (ON1/FON3/ON9 at 200 nM and Ce6 at 
20 M, section V.4.1) as reference.  
 
Figure V-12. No ICL formation was observed when using PON1/ON9/FON3 templated system at 200 nM concentration. 
a) RP HPLC analysis of the ICL experiment. The higher polarity of PON1 results in higher retention times under these 
analysis conditions (XBridge column, linear gradient of 0-20% ACN in 30 min). b) PAGE analysis of the same experiment 
visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
 
The failure of the current approach was rather unexpected, given the earlier positive 
experiences with a very similar system featuring an identical setup but containing methylene 
blue or rose Bengal conjugates.(1) 
However, upon closer inspection of the melting temperatures and consulting the literature, it 
seems that in the current case we had unfortunately chosen a sequence which is rather self-
complementary and where ON9:ON9 pairing is preferred over ON9:FON3 or ON9:PON1 pairing, 
and also over ON9:PON1+FON3 pairing thus resulting in a melting temperature corresponding 
to the melting of the ON9:ON9 duplex, explaining the high values observed in Table V.2. This 
then also explains the absence of any interstrand crosslinking as the envisaged complementarity 
between furan-probe and the target as well as the proximity of the PS-probe is unexisting. In 
view of time constraints, we decided not restart the entire process and synthesize alternative, 
more suitable sequences but rather concentrate on an alternative approach as described in the 
next chapter.  
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Table V-4. Comparison between the sequences used in this work and a previous study using MB or RB. 
Sequence used in this work Previous sequence 
      5’ - CAG ACA G2G TAC - 3’       5’ - CAG ACA G2G TAC - 3’ 
3’ - GTC TGT CCC ATG CGT GGG GCA GTC - 5’ 3’ - GTC TGT CCC ATG GAC CGT ACT AGT - 5’ 
                5’ - Ce6-Am6 - GCA CCC CGT CAG - 3’              5’ - RB or MB - CTG GCA TGA TCA - 3’ 
 
V.5.  Conclusions 
During this chapter, several self-activating systems were developed with the aim of targeting an 
unmodified ODN. However, all these systems proved to be problematic regarding their 
synthesis, handling and characterisation and at last failed to induce ICL formation towards the 
unmodified target.  
In the case of the self-activating probes, the presence of the PS in the same strand as the furan 
moiety is probably inducing premature oxidation of the latter, rendering it unreactive for 
crosslink formation.  
As an alternative, the templated system was designed. Keeping the PS and the furan moiety in 
different strands should ensure the stability during synthesis and also ICL formation using PS 
conjugated ODN was already successfully assessed during chapter IV. Previously, this approach 
was found to be successful during the study carried out in collaboration with Dr. Nathalie De 
Laet using methylene blue and rose bengal. However in the current case, problems with 
unexpected self-complementarity of the chosen sequences interfered with the evaluation of the 
potential of this strategy. A new strategy had in the meantime been designed, aimed at tackling 
the self-activating principle at the same time as solving the problem of oligonucleotide delivery 
to a cell, an approach which is described in the next chapter.  
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Chapter VI.  
Peptide based nanoparticles as activating delivery 
system for crosslinking oligonucleotides.  
 
In this chapter, an alternative to the self-activating systems described 
in the previous chapter is developed. The problematic synthesis and 
handling of the doubly modified probes, where the presence of the PS 
in the same strand as the furan leads to a premature activation of the 
latter, inspired us to design a system where the activating and reacting 
moieties are distributed among two different molecules. Rather than 
using the complementary strand of the furan ODN, which prevents the 
possibility of targeting an unmodified strand, a nucleic acid carrier was 
used instead. Considering that the potential use of the furan strategy 
in a cellular environment would need assistance to gain access to the 
cell, we hypothesized that the use of a photosensitiser-modified cell 
penetrating peptide will be able to fulfil two tasks: providing a delivery 
system and activating the furan moiety upon irradiation, thus resulting 
in a self-activating complex.   
 
  
94 
 
VI.1.  Introduction 
Nucleic acid based therapies have a great potential to treat an extensive variety of diseases. 
However, the main hurdle resides in the troublesome delivery of DNA and RNA based drugs, due 
to their size and highly anionic nature, (1) and therefore many efforts have been devoted to the 
development of carriers. (2–8) Moreover, nucleic acid drugs are readily degraded in the 
presence of enzymes and carriers that also protect them are desirable.  
Many delivery systems have been explored to overcome this bottleneck. Two main strategies 
can be distinguished: covalent attachment of the carriers to the nucleic acids (9) or the 
formation of supramolecular complexes. (10) Covalently bound systems present the advantage 
to be discrete, fully characterised complexes. However, there is a risk to compromise the activity 
of the nucleic acid drug and the synthesis of such bioconjugates is time and money consuming 
and especially problematic when the cargo is charged e.g RNA or DNA. (11) On the other hand, 
the noncovalent strategy stands out for the facile complex synthesis and the lower doses 
required to elicit a biological response. (10) 
The formation of noncovalent complexes between nucleic acids and carriers relies mainly on 
electrostatic interactions between the negatively charged nucleic acids and the positively 
charged carriers. Notably, the use of lipid based vectors to form lipoplexes has been widely 
studied (12–14), but they have not performed as expected in clinical trials, with low transfection 
efficiencies and high associated toxicity.  
As an alternative, the use of cell penetrating peptides (CPPs) has also been explored. CPPs are 
9-35mer cationic and/or amphipathic and are able to gain access into cells, taking their cargoes 
along. Most CPPs present positively charged residues that interact with the cell membrane 
before uptake and are also responsible for the electrostatic interactions with nucleic acids to 
form nanoparticles (NPs). 
Several CPPs have been used for nucleic acid complexation and delivery, namely: 
 MPG peptides: MPG was the first example reported of a CPP/DNA noncovalent complex 
that was able to induce vectorization of a cargo. MPG is a 27 residue amphipathic 
peptide that consist of a hydrophobic N-terminal domain derived from the fusion 
sequence of HIV gp41 and a hydrophilic C-terminal domain derived from the nuclear 
localization sequence (NLS) of SV40 T-antigen. (15) Several variants of this peptide have 
been reported to improve the transduction efficiency (16–18). Most of the MPG based 
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complexes were able to induce direct internalisation but the use of endocytic pathways 
was also observed. (18) 
 Pep peptides: these are amphipathic peptides with a similar design to MPG peptides but 
they differ in the hydrophobic domain that was modified to allow delivery of other 
cargos such as PNA, peptides and proteins. (19–21) 
 CADY peptides: these amphipathic CPPs were design for the more challenging delivery 
of plasmids. (22) 
 Polyarginine peptides: stearic acid-modified octaarginine was reported to successfully 
transduce plasmid DNA with an efficiency in the same range as LipofectamineTM. (23) 
However, unmodified polyarginines are mostly unsuited for nanoparticle formation. 
(23–25) Moreover, polyarginine peptides are associated with a higher cytotoxicity, 
limiting their application. (26) 
 Transportan and PepFects are chimeric CPPs that have been successfully used for ODN 
delivery (27), especially TP10. (28) PepFects consist of a series of chemically modified 
peptides (several of them using stearic acid) based on TP10 to render them more suited 
for supramolecular complex formation with nucleic acids. (24,29,30) 
For this study, a CPP derived from MPG, MPG-8, was chosen for the formation of supramolecular 
complexes with a furan containing ODN, due to its improved transduction efficiency compared 
to the other MPG analogues, its simpler synthesis and the availability of the N-terminus for 
modification.  
MPG-8 was designed by Divita et al. as a derivative of MPG shortened by 6 residues, resulting in 
a 21-mer peptide that was used for small interfering RNA (siRNA) delivery and was shown to 
compromise tumour growth using MPG-8/siRNA NPs to target cyclin B1. (17) 
Complexation between MPG-8 and a furan modified ODN should allow to evaluate the feasibility 
of ICL generation in the presence of a carrier, aiming to exploit the antisense potential of the 
furan methodology in a cellular context. In one of its variants, the antisense effect relies on the 
steric blockage of a mRNA molecule by hybridisation to a complementary ODN. Formation of an 
interstrand crosslink between the antisense ODN and the target mRNA is expected to improve 
the antisense effect, as has previously been reported using other crosslinking methodology. (31) 
For a successful ICL formation, recognition between the two complementary strands is required 
and entrapment of the furan ODN in the supramolecular complex may hinder the duplex 
formation. Highly negatively charged heparin has been widely used to induce nucleic acid 
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release from peptide based complexes by mimicking the interaction between the CPP and the 
heparansulfates proteoglycans that are present on the surface of most cells which seems to be 
a key process in the internalisation of several CPPs such as e.g. Tat and penetratin. (32–34) 
Besides, furan activation via 1O2 requires the presence of a PS and we rationalised that 
conjugation of the latter to MPG-8 will allow selective delivery of the dye, in close proximity to 
the furan ODN but avoiding the stability problems of the self-activating probe described in 
chapter 5. Ce6 was the PS of choice in view of the promising results obtained in previous 
chapters, and the Ce6 conjugated MPG-8 (Ce6MPG-8) was synthesised and evaluated for ODN 
complexation (figure VI-1). The resulting self-activating peptide-based NPs were studied for ICL 
formation with a complementary unmodified strand.  
 
Figure VI-1. Self-activating nanoparticle formation using Ce6MPG-8 and FON1.  
PS conjugated CPPs have been object of intense study in the last decades to construct third 
generation PS, i.e., PS attached to a targeting moiety. Applications include PDT, (35–38) 
antimicrobial PDT (39) and photochemical internalisation (40–43) showing that there is an 
inherent interest in the study of PS conjugated CPPs.   
  
VI.2.  Synthesis of MPG-8 and Ce6MPG-8 peptide conjugates 
First, MPG-8 peptide (tableVI-1) was synthesised following a modified version of the previously 
reported protocol (15–17). The synthesis was carried out on solid phase using Cysteamine 4-
methoxytrityl resin, to introduce the cysteamide moiety in the C-terminus (figure VI-2), and the 
obtained peptide was divided into two batches, still on the solid support. The first batch was 
cleaved using a mixture 94:2.5:2.5:1 of TFA/H2O/ EDT/TIS and purified by RP HPLC (figure VI-3). 
97 
 
The peptide was successfully identified by LC-MS analysis, showing also a small percentage of 
the oxidised MPG-8 form (due to the Met residue).  
 
Figure VI-2. MPG-8 synthesis starting from the cysteamine 4-methoxitrityl resin. 
Table VI-1. Sequence and modifications of the CPPs used in this chapter. 
Name  Sequence  Modification 
MPG-8              AFLGWLGAWGTMGWSPKKKRK-Cya Cya= cysteamide 
Ce6MPG-8 Ce6AFLGWLGAWGTMGWSPKKKRK-Cya 
Cya= cysteamide 
Ce6 
 
 
Figure VI-3. HPLC traces of MPG-8, a) before purification, at different wavelengths and b) the two fractions collected 
after purification. Luna C18 linear gradient of 0-100% ACN in 15 minutes. 
The second batch was used for conjugation to Ce6 via the N-terminus (figure VI-4). First, Ce6 
was activated with HBTU in the presence of DIPEA. Subsequent addition to the peptide, still 
attached to the solid support, was followed by cleavage under mild conditions using 0.1M HCl 
in HFIP instead of TFA (44) (mixture HCl in HFIP/EDT/TIS 96.5:2.5:1) to minimise degradation of 
the acid labile dye.  Still, after reaction and cleavage a complex mixture of compounds was 
obtained. After RP HPLC purification, three fractions were separated corresponding to the three 
main peaks (figure VI-5) and they were analysed by MALDI-TOF. In all three cases the expected 
mass was found, which is easily explained by the three carboxylic acids functionalities on Ce6, 
each of them susceptible to activation and functionalisation. The higher reactivity of HBTU 
seems to interfere with the selective conjugation towards one single carboxylic acid 
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functionality, whereas in chapter IV activation using DCC/NHS led to the formation of only one 
of three possible regioisomers. Moreover, two of the fractions also presented a 16Da excess, 
probably due to the presence of a Met residue that can be readily oxidised. The first fraction 
was used for the next experiments.  
 
Figure VI-4. Synthesis of Ce6MPG-8. 
 
Figure VI-5. HPLC traces of Ce6MPG-8, a) before purification, at different wavelengths and b) the three fractions 
obtained after purification. Jupiter C18 linear gradient of 0-100% ACN in 25 minutes 
 
VI.3.  Nanoparticle formation using MPG-8 peptide 
First, unmodified MPG-8 was used for the CPP/ODN complex formation, relying on the 
electrostatic interactions between the cationic groups of the peptide and the anionic residues 
of the ODN (figure VI-6). Incubation of 1 μM MPG-8 with 0.17 μM FON1 at 37ºC for 30 minutes 
in phosphate buffer, which corresponds to a 2.4 N/P ratio (molar ratio between the positively 
charged groups on the peptide and the PO4- groups on the ODN), as it was previously reported 
to be the optimal value for nucleic acid complexation using MPG-8 peptide (17), resulted in 
CPP/ODN nanoparticles. Since MPG-8 possess five positive charges (four from Lys residues and 
one from an Arg residue), 1 μM MPG-8 contains 5 μM positive charges. To keep the 2.4 ratio, 
the total concentration of negative charges should be 2.08 μM, which corresponds to 0.17 μM 
of FON1, since this ODN is a 12-mer containing 12 negative charges.  
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Formation of NPs was monitored by DLS showing an average size of 110 nm (figure VI-7). This 
NP size is in the same range as the complexes reported by Divita et al. showing the highest 
silencing efficiency. Formation of the NPs at higher concentrations or higher charge ratios lead 
to bigger size NPs, which tend to accumulate primarily in the liver, the spleen and the bone 
marrow. (45) 
 
Figure VI-6. Formation of NPs by electrostatic interaction between MPG-8 and FON1.  
 
Figure VI-7. DLS analysis of MPG-8/FON1 NPs using 1μM MPG-8 and 0.17μM FON1, 2.4 N/P ratio. 
 
VI.4.  Crosslink evaluation and optimisation using the MPG-8/FON1 NPs 
These NPs were evaluated for ICL formation by adding the complementary unmodified ODN, 
ON1 (Table VI-2), and Ce6 as PS, both in an equimolar concentration to FON1 (0.17 μM) as a 1:1  
PS/duplex ratio was established as the optimal condition for ICL in chapter 3.  The reaction 
mixture was then irradiated using red light and samples were taken at different times. In this 
case, only PAGE analysis was carried out since RP HPLC analysis proved troublesome, due to the 
presence of particles that resulted in system overpressures.  
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Table VI-2. Duplex used during the ICL evaluation using peptide based NPs. FON1 was complexed with the peptide and 
subsequently hybridised with the complementary strand ON1. 
Name Sequence  Modification 
FON1 5’ - CTG ACG GXG TGC - 3’ 
 
 
X=  
ON1 3’ - GAC TGC CCC ACG - 5’ - 
 
Unfortunately, no ICL formation was observed (figure VI-8) and it was hypothesized that FON1 
is not being released from the complex and therefore cannot recognise it complementary 
partner. 
 
Figure VI-8. No ICL formation was observed by PAGE analysis of the crosslink experiment using the MPG-8/FON1 NPs 
([duplex]= 0.17 M, [MPG-8]= 1 M) and Ce6 (0.17 M). Visualized using GelRedTM (20% polyacrylamide, 1x TBE 
buffer). 
The effect of heparin on ICL formation was then evaluated, to attempt release of FON1 from the 
peptide complex. To determine the necessary amount of heparin to induce the ODN release, the 
MPG-8 NPs were analysed by DLS after applying different amounts of heparin, ranging from 2-
200 eq. After addition of 10 eq, a new signal corresponding to a size of 5 nm appeared (figure 
VI-9a) and after addition of 100 eq this signal increased in intensity and the signal at around 
100nm (corresponding to the NPs) was not observed anymore, being replaced by a signal at 
around 300 nm, indicating a change in the complex structure (figure VI-9b).  
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Figure VI-9. DLS analysis of peptide/FON1 NPs using 1μM MPG-8 and 0.17μM FON1, 2.4 N/P ratio adding heparin a) 
10 eq and b) 100 eq. 
Based on the DLS results, a new crosslink experiment using the MPG-8/FON1 complex was 
designed. First, the NPs were formed by incubation as described in section VI.3, followed by 
addition of ON1 and Ce6 in an equimolar concentration to FON1. After irradiation for 5 minutes, 
100 eq heparin were added to assess whether competition of the anionic heparin facilitates 
FON1 release and irradiation proceeded for 5 minutes more.  
As a reference, a crosslinking experiment was separately carried out using the FON1/ON1 duplex 
and Ce6 using identical conditions ([duplex] = [Ce6] =  0.17 M) as when using the peptide NPs 
but MPG-8 peptide (1 M) and heparin (100 eq) were only added after irradiation for 10 
minutes. This experiment was also loaded during PAGE analysis to ensure correct assignment of 
the crosslink adduct band, since the presence of the peptide or heparin may influence its 
migration on the gel.   
As can be observed in figure VI-10 heparin addition indeed seems to help the crosslink 
formation. However, irradiation after heparin addition does not increase the amount of ICL 
formed, suggesting that maybe FON1 was partially consumed as 1O2 was still generated in spite 
of FON1 not being able to hybridise to ON1. For further experiments, heparin will be added 
before irradiation to maximise ICL formation. 
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Figure VI-10. PAGE analysis of ICL formation using the MPG-8/FON1 NPs ([duplex] = 0.17 M, [MPG-8] = 1 M) and 
Ce6 (0.17 M), adding 100 eq heparin after 5 min irradiation. Reference ICL: [duplex] = [Ce6] = 0.17 M, adding [MPG-
8] = 1 M and 100 eq heparin after the irradiation finishes. Visualized using GelRedTM (20% polyacrylamide, 1x TBE 
buffer). 
 
VI.5. Evaluation of Ce6 concentration for ICL formation 
Another parameter that was optimised was the amount of Ce6 added. It was determined in 
chapter III that an equimolar ratio between the duplex and Ce6 was optimal to induce crosslink 
formation using this PS. During the crosslinking experiments carried out in this chapter, that 
ratio was therefore maintained but the concentration needed to be decreased more than 10 
times (from 2 to 0.17 M) in order to keep a 2.4 charge ratio between the MPG-8 and FON1 and 
a 1 M concentration of MPG-8, for successful formation of NP of the desired size. However, 
the presence of the peptide and heparin might interfere with the 1O2 generation by acting as 
quenchers of the excited state of Ce6 or even reacting with 1O2, resulting in low yielding ICL. It 
is worth noticing that a lower Ce6 concentration itself does not seem to be an issue since the 
reference crosslink (section IV) was carried out at [Ce6]= 0.17 M but without the presence of 
heparin or MPG-8 during irradiation.  
Using the conditions previously stablished, we set out to compare the ICL formation using 0.17 
and 2 M Ce6 concentration (in both experiments MPG-8 concentration was still 1 M and FON1 
0.17 M).  
After incubation of the MPG-8/FON1 NPs, addition of ON1, Ce6 and heparin was followed by 
irradiation (figure VI-11). PAGE evaluation of the samples taken a different times showed that 
indeed, an increased amount of Ce6 results in a higher yielding crosslinking (figure VI-12) 
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Figure VI-11. Schematic representation of FON1 release by heparin addition before irradiation. 
 
 
Figure VI-12. PAGE analysis of ICL formation using the MPG-8/FON1 NPs ([duplex]= 0.17 M, [MPG-8]= 1 M, 100 eq 
heparin) and Ce6 at two different concentrations, 0.17 and 2 M. Visualized using GelRedTM (20% polyacrylamide, 1x 
TBE buffer). 
Moreover, the need for the use of heparin to induce release was also assesed under this higher 
Ce6 concentration (figure VI-13). In agreement with previous experiments, the presence of 
heparin (100 eq) had a positive effect on the ICL formation.  
 
Figure VI-13. PAGE analysis of ICL formation using the MPG-8/FON1 NPs ([duplex] = 0.17 M, [MPG-8]= 1 M) and 
Ce6 at 2 M in the presence or absence of heparin. Visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
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VI.6.  Nanoparticle formation using Ce6MPG-8 peptide 
Once the conditions for ICL formation using peptide based nanoparticles were optimised using 
unmodified MPG-8, we set out to characterise and evaluate the complexes made using 
Ce6MPG-8 in combination with FON1, which results in a self-activating system (figure VI-14). 
 
Figure VI-14. Schematic representation of NP formation using Ce6MPG-8 and FON1. 
The same incubation procedure as in section VI.3 was used, consisting of mixing Ce6MPG-8 (1 
M) and FON1 (0.17 M) for 30 minutes at 37ºC, in this case keeping the solution in the darkness 
to avoid premature 1O2 generation.  
DLS analysis of the Ce6MPG-8/FON1 NPs showed that in this case the NP size obtained is 130 
nm (figure VI-15).  
 
Figure VI-15. DLS analysis of Ce6MPG-8/FON1 NPs using 1μM Ce6MPG-8 and 0.17μM FON1, 2.4 N/P ratio 
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VI.7.  ICL using self-activating nanoparticles 
Ce6MPG-8/FON1 NPs were mixed with the complementary ON1 and 100 eq of heparin. The 
reaction mixture was irradiated using red light for 10 min and samples were taken and analysed 
by PAGE, showing that ICL formation did occur without any external PS added (figure VI-16).  
 
Figure VI-16. PAGE analysis of ICL formation using Ce6MPG-8/FON1 NPs ([duplex] = 0.17 M, [Ce6MPG-8] = 1 M) 
in the presence of heparin. Visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
Next, we set out to assess the influence of heparin on the ICL generation using the Ce6MPG-
8/FON1 complexes and also to establish a comparison between the use of the self-activating 
system and Ce6 externally added. For this purpose, four different crosslink experiments were 
carried out and loaded on the same gel, allowing a direct comparison. For all experiments, the 
peptide concentration was 1 M and the duplex concentration was 0.17 M.  
For the first two experiments, Ce6 was used in solution at 1 and 2μM in the presence of heparin 
whereas for the third and fourth experiments, Ce6MPG-8 was used and no external PS was 
added and heparin was only added in the third one (table in figure VI-17). 
Only a slight difference in ICL formation can be observed between the experiments where 1 or 
2 M of Ce6 is used experiment. However, there is a substantial difference between the ICL 
formation when Ce6 is used in solution or attached to MPG-8, being lower in the latter. This 
result may be explained by a lower 1O2 generation as it was previously observed that a lower 
Ce6 concentration had a dramatic effect on the crosslink formation. Unfortunately, in this case 
the PS concentration cannot be easily tuned as this would mean an increase in the peptide 
concentration as well, which would result in an increase in the NP size. Moreover, in the 
experiments using the unmodified MPG-8 and Ce6 in solution, the PS was only added after 
incubation at 37ºC, to avoid any potential degradation. However, during the experiments using 
Ce6MPG-8 this was not a possibility and it cannot be ruled out that Ce6 was damaged during 
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this process. A way to overcome this would be to use more stable PSs and/or a PS with higher 
1O2 quantum yield than Ce6.  
Last, heparin addition showed to have a smaller influence on the ICL formation using the 
Ce6MPG-8/FON1 complexes. The bigger size of these NPs seems to suggest that the presence 
of Ce6 results in bigger and maybe looser complexes that allow an easier recognition between 
FON1 and ON1 even without the presence of heparin.  
 ICL 1 ICL 2 ICL 3 ICL4 
[Peptide] (M) [MPG-8]=1 
[MPG-
8]=1 
[Ce6MPG-
8]=1 
[Ce6MPG-
8]=1 
[Duplex] (M) 0.17 0.17 0.17 0.17 
[Ce6] 2 1 - - 
Heparin 100 eq 100 eq 100 eq - 
 
Figure VI-17. PAGE analysis of ICL formation using MPG-8/FON1 or Ce6MPG-8/FON1 NPs under different conditions 
as presented in the table. Visualized using GelRedTM (20% polyacrylamide, 1x TBE buffer). 
 
VI.8.  Conclusions 
In this chapter, a new self-activating system based on the use of MPG-8 peptide was designed 
and evaluated. Preliminary experiments where unmodified MPG-8 was complexed with FON1 
and Ce6 was added in solution to induce ICL showed that crosslink formation is possible in the 
presence of a CPP as carrier, once conditions such as 1O2 generation and furan ODN availability 
are optimised.   
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Next, self-activating NPs were formed and their crosslinking capacities were evaluated. 
Ce6MPG-8 successfully complexed FON1 and induces crosslink formation with the 
complementary strand, although to a lower extent than when Ce6 was added in solution, 
probably due to an insufficient 1O2 generation and therefore the use of a different PS would be 
advantageous. Moreover, the need for heparin to allow ODN release and duplex formation 
seemed to be less acute in this case, maybe due a looser complex caused by the presence of Ce6 
in the NPs.  
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Chapter VII. 
Conclusions and perspectives.  
 
Many efforts have been devoted in the last decades to unravel the intricate puzzle that conforms 
all the roles that nucleic acids play in living beings. Not only do they define the genetic makeup 
of a given organism but they also participate in enzymatic processes and regulate gene 
expression. Therefore, the development of new tools that may serve for diagnosis or therapy 
based on those processes is of high interest.  
It was previously stablished in the OBCR group that introduction of a furan moiety into an 
oligonucleotide could be easily achieved by automated synthesis resulting in a probe equipped 
with a masked reactive moiety that could induce the formation of a selective interstrand 
crosslink with a complementary sequence upon furan oxidation. Furan oxidation can be 
achieved using NBS or, in a more biocompatible fashion, singlet oxygen, and for the latter 
methylene blue and rose bengal were thoroughly studied. 
The aim of the present study is to expand this methodology to the use of porphyrin based 
photosensitisers for singlet oxygen generation with the final aim to develop a method that can 
be applicable in a cellular context.  
Three different porphyrin based photosensitisers were selected: the commercially available 
chlorin e6 (Ce6), a tripyridyl porphyrin (TriPyCOOH) and a zinc phthalocyanine decorated with 
tert-butyl groups (TT1).  
 
First, the ability of each photosensitiser to induce interstrand crosslink when they were added 
in solution was assessed. For this purpose, a furan modified oligonucleotide was hybridised with 
its complementary strand in the presence of the respective photosensitisers and, upon light 
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irradiation, the crosslink generation was evaluated. Careful optimisation of several factors was 
performed, including reaction time, photosensitiser concentration, ratio between the duplex 
and the photosensitiser and type of light. It was found that the use of Ce6 results in the most 
extensive crosslink generation (52% conversion) among the three photosensitisers when the 
optimal conditions were used. TriPyCOOH also allowed generating the crosslink adduct in good 
yields whereas TT1 was only able to do so to a low extent, due to the high insolubility of this 
compound in the aqueous conditions under which the reaction was carried out.  
 
Next, it was hypothesised that conjugation of the photosensitisers to the complementary strand 
of the furan oligonucleotide would result in two important improvements: singlet oxygen 
generation in close proximity to the furan moiety and higher water solubility of the 
photosensitisers.  
Different conjugation conditions were explored for each photosensitiser, based on activation of 
the carboxylic acid functionality in the dyes and subsequent addition of an amino modified 
oligonucleotide. TT1 conjugation was particularly challenging and the reaction had to be 
performed when the oligonucleotide was still attached to the solid support where it was 
synthesised, in order to avoid the used of aqueous conditions and concurrent solubility 
problems with TT1.  
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With the three conjugates in hands, they were hybridised to the furan containing 
oligonucleotides and the crosslink generation was evaluated. Again, the highest crosslink 
formation occurred when using the Ce6 conjugate, thanks to a sufficient singlet oxygen 
generation by this complex and a duplex stabilisation caused by the introduction of the chlorin. 
Surprisingly, the TriPyCOOH conjugated oligonucleotide was not able to induce a crosslinking 
presumably due to the large duplex stabilisation induced by the introduction of the porphyrin 
and a low singlet oxygen generation by the latter. The TT1 conjugated oligonucleotide showed 
a high singlet oxygen generation and allowed forming a crosslink but to a lower extent since the 
duplex was also destabilised due to the presence of the dye.  
 
With the idea to allow crosslinking to target unmodified nucleic acid targets, the synthesis and 
evaluation of dual modified furan/photosensitiser probes was attempted. However, synthesis 
and handling of these self-activating probes was troublesome, probably due to premature 
singlet oxygen generation and inactivation of the probe, and when the crosslinking reaction was 
attempted it was never successful.  
 
As an alternative, the use of a templated system was tested where the furan and the 
photosensitiser were placed in two different oligonucleotides, targeting a longer, unmodified 
strand, that brings both sequences in close proximity. While this approach had proven successful 
when using methylene blue or rose bengal modified probes, we here were not able to 
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demonstrate successful crosslinking. Time constraints that did not allow to investigate the 
system more in detail also because an alternative approach (vide infra) proved more successful. 
 
Indeed, as a further alternative, the use of a photosensitiser modified peptide carrier was 
explored. Nucleic acids are not able to gain access inside cells and the use of so-called cell 
penetrating peptides has been described to assist in the delivery of these compounds into cells 
for nucleic acid based therapies. More specifically, when using certain CPPs, supramolecular 
complexation between the positively charge peptide and the negatively charged oligonucleotide 
occurs spontaneously, resulting in the formation of nanoparticles.  
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Here, the amphipathic 21 residue MPG-8 peptide was chosen for complexation with the furan 
oligonucleotide. Upon addition of the complementary unmodified strand and a sufficient 
amount of Ce6 as photosensitiser, crosslinking formation occurred, assisted by the presence of 
heparin to allow the release of the furan oligonucleotide when needed. Subsequently, the MPG-
8 peptide was conjugated to Ce6 and complexation of this functionalised cell penetrating 
peptide with the furan oligonucleotide resulted in the formation of self-activating nanoparticles 
that were able to induce crosslink formation with an unmodified complementary 
oligonucleotide.  
 
Perspectives  
Since one of the applications of the furan technology could be its application for gene based 
therapy (antisense or antigene), the construction of the self-activating peptide nanoparticles 
opens the way to the use of the furan methodology in a cellular environment since it not only 
allows delivery but also protection of the oligonucleotides towards enzymatic degradation. 
Evaluation of alternative photosensitisers with higher singlet oxygen quantum yields might 
result in higher crosslinking yields.  
Moreover, an unexplored possibility is the use of furan containing oligonucleotides for single 
stranded nucleic acid recognition for diagnosis and forensics. High-throughput analysis of 
nucleic acids sequences such as sequencing rely on hybridisation and there is a great potential 
for the use of the furan technology to improve the sensitivity of this techniques, especially in 
particularly challenging cases such as detection of single nucleotide polymorphisms.   
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Chapter VIII. 
Nederlandse samenvatting.  
 
Het ontrafelen van alle functies die nucleïnezuren vervullen vormde gedurende het laatste 
decennium een belangrijk onderwerp van onderzoek binnen vele onderzoeksgroepen 
wereldwijd. Niet alleen vormen nucleïnezuren de basis van het genetisch materiaal, bovendien 
nemen ze deel aan belangrijke enzymatische processen en genregulatie. Het ontwikkelen van 
nieuwe tools die kunnen dienen voor diagnose of therapie is daarom van groot belang in deze 
context. 
Voorafgaandelijk onderzoek binnen OBCR toonde aan dat introductie van een furan eenheid in 
een oligonucleotide eenvoudig bewerkstelligd kan worden via automatische synthese 
resulterende in een probe die uitgerust is met een gemaskeerde reactieve entiteit. Deze is in 
staat is om, na furan oxidatie, crosslinking te veroorzaken met een complementaire sequentie. 
Furan-oxidatie kan bekomen worden door behandeling met NBS of op een meer biocompatibele 
wijze door het genereren van singlet zuurstof met behulp van Bengaals roze of methyleenblauw. 
Het doel van huidige studie is het uitbreiden van deze methodologie naar het gebruik van 
porphyrine gebaseerde fotosensitizers voor singlet zuurstof generatie met het finale doel om 
een methode te ontwikkelen dit toepasbaar kan zijn in een cellulaire context. 
Drie verschillende porphyrine gebaseerde fotosensitizers werden hiertoe geslecteerd: het 
commercieel beschikbaar chlorin e6 (Ce6), een tripyridyl porphyrine (TriPyCOOH) en een zink 
phthalocyanine gedecoreerd met tert-butyl groepen (TT1).  
 
 
 
118 
 
In eerste instantie werd de performantie van elke 
fotosensitizer getest door toevoegen in 
oplossing.  
 
In tweede instantie werd nagegaan of conjugatie van de fotosensitizers aan het oligonucleotide 
complementair aan het furan-oligo verbetering kon brengen door het genereren van singlet 
zuurstof in de buurt van de furan eenheid en door een verhoogde oplosbaarheid van de 
fotosensitizers door conjugatie met de oligo’s. Hiertoe dienden methoden ontwikkeld worden 
voor het conjugeren van de 
fotosensitizers aan de oligonucleotiden. 
Dit gebeurde door middel van activatie 
van een carbonzure functie op de 
fotosensitizers en reactie met een amino 
gemodificeerd oligo. 
De hoogste crosslink performantie 
werd , zowel in oplossing als voor de 
geconjugeerde oligo’s waargenomen 
voor het Ce6-conjugaat, mede door 
een voldoende singlet zuurstof 
generatie gecombineerd met een 
stabilisatie van de duplex door introductie van het chlorine. 
Met het idee om crosslinking te bewerkstelligen met een niet-gemodificeerd 
nucleïnezuurtarget, werden vervolgens dubbel gemodificeerde furan/fotosensitizer probes 
aangemaakt. Helaas bleek synthese en 
manipulatie van deze zelf-activerende 
probes geen sinecure mede door 
premature singelt zuurstof generatie 
en daarmee gepaard gaande inactivatie 
van de probes.  
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Als een volgend alternatief, werd het gebruik van een fotosensitizer-gemodificeerde 
peptidedrager geëxploreerd. Nucleïnezuren op zich kunnen niet opgenomen worden door cellen 
en het gebruik van zogenaamde celpenetrerende peptiden werd beschreven als een 
mogelijkheid om het afgeven van zulke verbindingen in cellen te bewerkstelligen in de context 
van nucleïnezuur gebaseerde therapieën. Meer bepaald worden bij het gebruik van bepaalde 
celpenetrerende peptide 
supramoleculaire complexen 
gevormd bestaande uit het 
positief geladen peptide en 
het negatief geladen oligo wat 
kan resulteren in de vorming 
van nanopartikels. 
Het amfipatische 21-meer MPG-8 peptide werd gekozen voor complexatie met een furan oligo. 
Bij toevoeging van de complementaire streng en een voldoende hoeveelheid Ce6 als 
fotosensitizer, kon crosslinking waargenomen worden wanneer ook heparine werd toegevoegd 
om vrijstellen van het furan-oligo toe te laten. Vervolgens werd het MPG-8 peptide 
geconjugeerd met Ce6 en complexatie van dit gefunctionaliseerde celpenetrerende peptide met 
het furan oligo resulteerde in de vorming van zelfactiverende nanopartikles die in staat bleken 
te zijn crosslinkingvorming te induceren met een niet-gemodificeerde target 
nuceïnezuursequentie.  
 
Perspectieven  
De constructie van zelf-activerende peptide nanopartikels opent de weg naar het gebruik van 
furan methodologie in een cellulaire context aangezien dit niet alleen afgifte toelaat maar 
bovendien ook de oligonucleotiden beschermt tegen degradatie. Evaluatie van fotosensitizers 
met hogere singlet zuurstof quantum opbrengst zou kunnen resulteren in hogere 
crosslinkrendementen.   
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Chapter IX. 
Resumen en español. 
 
Muchos esfuerzos se han dedicado durante las últimas décadas a desvelar el intrincado puzle 
que conforman todos los papeles que juegan los ácidos nucleicos en los seres vivos. Los ácidos 
nucleicos no solo definen la constitución genética de un organismo sino que también participan 
en procesos enzimáticos y regulan la expresión genética. Por todo ello, existe un gran interés en 
el desarrollo de nuevas herramientas que puedan ser útiles en aplicaciones para diagnósticos o 
terapia basadas en estos procesos. 
Previamente, se ha sido establecido en el grupo OBCR (Organic and Biomimetic Chemistry) que 
la introducción de un grupo furano en un oligonucleótido puede logarse de forma sencilla 
utilizando síntesis automática. Como resultado se obtiene una sonda equipada con un grupo 
funcional altamente reactivo que ha sido enmascarado y es capaz, una vez que el grupo furano 
ha sido oxidado, de producir un entrecruzamiento entre cadenas de forma selectiva con la 
secuencia complementaria. La oxidación del grupo furano se puede lograr o bien usando NBS o 
bien, de una forma más biocompatible, usando oxígeno singlete. Para la formación de este 
último, los compuestos azul de metileno y rosa de bengala han sido estudiados en detalle.  
El objetivo de este estudio es expandir esta metodología al uso de fotosensibilizadores 
porfirínicos para la generación de oxígeno singlete con el objetivo final de desarrollar un método 
que se pueda aplicar en un contexto celular.  
Para ello, se seleccionaron tres fotosensibilizadores distintos: la clorina e6 (comercial), una 
porfirínica tripiridínica (TriPyCOOH) y una ftalocianina de zinc decorada con grupos tert-butilo.  
(TT1). 
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Primero, se evaluó la habilidad de cada fotosensibilizador para producir el entrecruzamiento 
entre cadenas cuando se añaden en solución. Para ello, un oligonucleótido modificado con un 
grupo furano fue hibridado con la cadena complementaia en presencia del respectivo 
fotosensibilizador para evaluar la generación del entrecruzamiento una vez se produce la 
irradiacción necesaria. Una cuidados optimización de varios factores se llevó a cabo, incluyendo 
el tiempo de reacción, la concentración de los fotosensibilizadores, el ratio entre el dúplex y el 
fotosensibilizador y el tipo de luz utilizada. Fue hallado que de los tres fotosensibilizadores, el 
uso de Ce6 produce los rendimientos de entrecruzamiento más altos (conversión del 52%) 
cuando las condiciones son óptimas. TT1 fue capaz de producir el entrecruzamiento solo a bajos 
rendimientos, debido a su insolubidad en condiciones acuosas que son necesarias para esta 
reacción.  
 
En el siguiente paso, se planteó la hipótesis de que al conjugar los fotosensibilizadores a la 
cadena complementaria al oligonucleótido que contiene el grupo furano resultaría en dos 
mejoras importantes: la generación de oxígeno singlete se produciría cerca del grupo furano y 
la solubilidad en agua de los fotosensibilizadores sería mayor.  
Para conjugar cada fotosensibilizador se usó una estrategia de conjugación distinta, todas ellas 
basadas en la activación del ácido carboxílico en los fotosensibilizadores seguida por la adicción 
de un oligonucleótido que contiene un grupo amino. La conjugación de la TT1 fue 
particularmente problemática y esta reacción tuvo que llevarse a cabo con el oligonucleótido 
todavía en el soporte sólido donde se había sintetizado, para evitar el uso de condiciones 
acuosas y los problemas de solubilidad asociados.  
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Una vez que los tres conjugados fueron sintetizados, se hibridaron al oligonucleótido que 
contiene el grupo furano y se evaluó la generación del entrecruzamiento. De nuevo, el 
entrecruzamiento que dio lugar a los rendimientos más altos fue en el que se usó el conjugado 
con Ce6, gracias una generación suficiente de oxígeno singlete y a una estabilización del dúplex 
que ocurre como consecuencia de introducir Ce6 en el oligonucleótido. Sorprendentemente, el 
uso del conjugado con TriPyCOOH no fue capaz de producir el entrecruzamiento, 
presuntamente debido la gran desestabilización que tiene lugar al introducir este 
fotosensibilizador y la pobre generación de oxígeno singlete. El conjugado con la TT1 mostró una 
alta generación de oxígeno singlete y fue capaz de producir el entrecruzamiento entre cadenas 
pero con rendimientos menores debido a una desestabilización del dúplex debido a la presencia 
del fotosensibilizador.  
 
Con la idea de permitir el entrecruzamiento con una secuencia no modificada, se sintetizaron y 
evaluaron sondas doblemente modificadas con un grupo furano y un fotosensibilizador. Sin 
embargo, la síntesis y el manejo de estas sondas auto-activables fue problemática, 
probablemente debido a la generación prematura de oxígeno singlete y la consiguiente 
desactivación de las sondas, y cuando la reacción de entrecruzamiento se intentó llevar a cabo 
no tuvo éxito en ningún caso.  
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Como alternativa, se probó el uso de un sistema plantilla en el que el furano y el 
fotosensibilizador fueron introducidos en oligonucleótidos distintos y posteriormente 
hibridados a un oligonucleótido más largo sin modificaciones, que los mantiene próximos el uno 
al otro. Mientras que este enfoque tuvo éxito en un estudio anterior en el que se usaron sondas 
que contenían azul de metileno y rosa de bengala, en nuestro caso no pudimos demostrar la 
generación del entrecruzamiento. Debido a falta de tiempo, este enfoque no fue estudiado en 
más detalle ya que una tercera estrategia fue puesta en práctica (vide infra).  
 
En esta nueva estrategia se estudió el uso de un péptido de penetración celular como 
transportador. Los ácido nucleicos no son capaces de ganar acceso a las células y se ha descrito 
el uso de estos péptidos para terapias basadas en el uso de ácidos nucleicos ya que son capaces  
de asistir en la internalización de los ácidos nucleicos. En concreto, algunos de estos péptidos 
son capaces de formar complejos supramoleculares entre los péptidos cargados positivamente 
124 
 
y los oligonucleótidos cargados negativamente, lo que resulta en la formación de 
nanopartículas.  
 
En este caso, el uso del péptido conocido como MPG-8, que contiene 21 aminoácidos, se eligió 
para la formación de complejos con el oligonucleótido que contienen el furano. Al añadir la 
cadena complementaria y una concentración suficiente de Ce6 como fotosensibilizador, se 
observó la formación del entrecruzamiento, usando heparina para facilitar la liberación del 
oligonucleótido cuando es necesario. Posteriormente, MPG-8 fue conjugado a Ce6 y la 
formación del correspondiente complejo con el oligonucleótido que contiene el furano resultó 
en la formación de nanopartículas auto-activables que fueron capaces de producir el 
entrecruzamiento con un oligonucleótido no modificado.  
 
Perspectivas  
Ya que una de las aplicaciones de esta tecnología basada en el grupo furano podría ser para 
terapia genética, la  formación de nanopartículas auto-activables abre las puertas al uso de esta 
metodología en un contexto celular, ya que no solo permite internealizar oligonucleótido sino 
que también los protege contra la degradación enzimática.  La evaluación de otros 
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fotosensibilizadores con rendimientos cuánticos mayores podría resultar en la producción de 
entrecruzamientos con mayores rendimientos.  
Además, una posibilidad inexplorada es el uso de oligonucleótido que contiene el furano para el 
reconocimiento de ácidos nucleicos de cadena simpe para terapia y diagnóstico. Los análisis de 
alto rendimiento (high-throughput) de secuencias de ácidos nucleicos como por ejemplo el 
secuenciamiento están basados en la hibridación y el uso de la tecnología del furano tiene 
mucho potencial para mejorar la sensibilidad de estas técnicas, especialmente en casos 
problemáticos como la detección de polimorfismos de un único nucleótido.     
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Chapter X. 
Materials and methods. 
 
X.1. Small molecule materials and methods  
All chemical reagents and solvents were purchased from Sigma Aldrich, Glen Research, 
Livchem Logistics and used without further purification. Photosensitisers were obtained via 
a collaboration between UGent and the University of Aveiro and the Autonomous University 
of Madrid in the context of an ITN.  
X.1.1.Furan phosphoramidite 
The furan building blocks for incorporation into the modified oligonucleotides was 
synthesised as previously described.(1,2) 
X.1.2.Photosensitiser synthesis:  
TriPyCOOH porphyrin (3) and TT1 phthalocyanine (4) were synthesised as previously 
described. Chlorin e6 (Ce6) was purchased from Livchem Logistics. 
 
X.2. Oligonucleotide materials and methods 
All chemical reagents and solvents were purchased from Sigma Aldrich, Glen Research, Livchem 
Logistics. Oligonucleotides were purchased from Eurogentec.  
X.2.1.Oligonucleotides synthesis  
Oligonucleotides were synthesized at 1 μmol scale on an ABI 394 DNA synthesizer. The 
sequences were synthesized on solid phase and the last nucleoside remained DMT-protected 
for later SEP-PAK purification, unless otherwise stated. 
X.2.1.1. Synthesis of furan modified oligonucleotides 
Synthesis (DMT-On) proceeded through an automated phosphoramidite coupling 
cycle and was interrupted for a manual incorporation of the furan modified 
phosphoramidites. This coupling involved an alternating application of a dry 0,05 M 
solution of the modified phosphoramidite in acetonitrile and a dry 0,1 M 
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dicyanoimidazole solution in acetonitrile, over 30 min. Then, and a mixture of Cap A 
(0.5 mL, ) and Cap B (0.5 mL) was pushed over the column, after which it was again 
flushed with acetonitrile (1 mL) and automated synthesis was resumed. 
X.2.1.2. Synthesis of on solid support amino modified oligonucleotides 
The DMS(O)MT-amino modifier was installed on the synthesiser as an extra 
nucleobase. After incorporation at the 5’ end of the growing ON, the amino group 
was deprotected on column by treatment with 5 mL TCA, 10 mL ACN, 5 mL 20% 
Et2NH in ACN and 10 mL of ACN.  
X.2.1.3. Synthesis of internally amino modified oligonucleotides  
The trifluoroacetyl protected dT amino modifier was installed on the synthesiser as 
an extra nucleobase. After oligonucleotide synthesis, deprotection of the amino 
group occurs during the standard treatment with NH4OH.  
X.2.2.Oligonucleotide cleavage, deprotection and purification 
The synthesized oligonucleotides were cleaved of the solid support by treatment with 1 
mL of aqueous NH4OH while shaking overnight at a temperature of 55°C.  
Purification with concurrent DMT removal of the synthesized oligonucleotides was 
carried out using a Sep-Pak C18 cartridge obtained from Waters. After equilibrating the 
cartridge using ACN and a 5 mM solution of TEAA, the oligonucleotides were loaded and 
the following solutions were eluted: an aqueous solution of NH4OH (2.5%), milliQ water, 
an aqueous solution of TFA (1.5%), milliQ water and finally 20% ACN in water to elute 
the desired oligonucleotide. The fractions were combined and analysed by RP HPLC and 
MALDI-TOF. 
 
X.2.3.Oligonucleotide conjugation 
Conjugation of the PS to the amino modified ODNs was performed by activating the 
carboxylic acid functionality on the dyes and subsequent addition of the amino ODN in 
buffer solution. 
X.2.3.1. Conjugation to Ce6 
DCC (64 eq) and NHS (64 eq) were added in DMF to chlorin e6 (1 mg, 64 eq) and 
the solution stirred for 1 h in the darkness under Ar atmosphere. Then, a 0.1 M 
aqueous solution of NaHCO3 (30 µL, pH 8.3) and the amino modified 
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oligonucleotide (30 nmol) were added and the solution was stirred at room 
temperature for 18h in the darkness. Subsequently, 2x500 L of mQ water were 
added and the resulting mixture centrifuged. The supernatant was collected, 
combined and lyophilised. The desired conjugate was obtained by purification via 
RP HPLC equipped with a Discovery BIO Wide Pore C5 column (linear gradient: 0-
50% ACN in 15 min) and analysed by MALDI-TOF. 
X.2.3.2. Conjugation to TriPyCOOH 
TriPyCOOH was provided as the NHS ester (TriPyCOONHS). Conjugation with the 
amino modified oligonucleotides was carried out as follows: TriPyCOONHS (1 mg, 
hen a 0.1 M aqueous solution of NaHCO3 
the solution stirred in the darkness at room temperature under Ar atmosphere for 
he resulting mixture 
centrifuged. The supernatant was collected, combined and lyophilised. The desired 
conjugate was obtained by purification via RP HPLC equipped with a Discovery BIO 
Wide Pore C5 or an Aeris Wide Pore column (0-50% ACN in 15 min or 0-10% ACN in 
15 min then 10-100% ACN in 15 min, respectively) and analysed by MALDI-TOF MS. 
X.2.3.3. Conjugation to TT1 
Conjugation using TT1 phthalocyanine was performed while the amino modified 
oligonucleotide was still attached to 1000 Å Control Pore Glass (CPG) as in the 
procedure followed by Kopecky et al.(5): 
TT1 phthalocyanine (1 mg, 12 eq) was premixed with HBTU (10 eq) and DIPEA (6 
µL) in DMF (30 µL) and added in 3 portions to the CPG (3 mg, aprox. 99 nmol of the 
oligonucleotide), every 1h. The mixture was shaken for 24h at 55º in the darkness. 
Subsequently, the mixture was washed with 3x500 L DMF, 3x500 L ACN and 
3x500 L Et2O, then dried. Cleavage from the solid support was carried out adding 
1mL of NH4OH was added and the mixture shaken overnight at 55 ºC in the 
darkness. The crude was pre-purified using Sep-Pak C18 cartridge (Waters) and the 
fractions eluted with 50% ACN were collected, combined and lyophilized.  
The residue was purified via RP HPLC equipped with a Discovery BIO Wide Pore C5 
(linear gradient: 0-80% ACN in 15 min) and analysed by MALDI-TOF MS 
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X.2.4.Oligonucleotide analysis and characterisation 
X.2.4.1. RP HPLC analysis 
Oligonucleotides were analysed by RP-HPLC, using an Agilent 1200 system. The 
mobile phases consisted of A/acetonitrile and B/0,1 M TEAA buffer containing 5% 
acetonitrile. Furan and amino modified oligonucleotides were analysed using a 
Phenomenex Clarity 110 Å C18 column (250 x 4.6 mm, 5 μm), a Phenomenex Aeris 
Widepore column (150 x 4.6 mm, 3.6 μm) or a Waters XBridge 130 Å Oligonucleotide 
C18 column (2,5 μm, 4,6 mm X 50 mm) used at 50°C (linear method 0-20% ACN in 
30 min). 
The photosensitiser conjugated ODN were analysed and purified using RP HPLC 
equipped with a Discovery BIO Wide Pore C5 column (5 μm, 15 cm x 4,6 mm) and 
the mobile phases consisted of A/acetonitrile and B/0,1 M TEAA buffer containing 
5% acetonitrile.  
 
X.2.4.2. MALDI-TOF analysis 
Masses of the oligonucleotides were determined by MALDI-TOF analysis on an ABI 
Voyager DE-STR MALDI-TOF. The oligonucleotide samples were mixed with a matrix 
consisting of 3-hydroxypicolinic acid (17 mg in 100 μL milliQ) and ammonium citrate 
(50 mg in 200 μL milliQ and 250 μL acetonitrile) present in a 9:1 ratio, in a 1:1 
sample:matrix ratio. After mixing with the matrix, the samples were desalted by 
treatment with DOWEX beads. The samples were spotted on a MALDI plate, together 
with a commercial oligonucleotide sequence with a known mass (5’-GCA TCT CGT 
CAG-3’), purchased from Eurogentec, for calibration of the measurement.  
X.2.4.3. UV analysis 
Concentrations and UV-Vis spectrum (in the case of the photosensitiser conjugates) 
of the ODNs solutions were measured on the Trinean DropSense96 UV/VIS droplet 
reader, using 2 μL sample for each measurement. Each sample was measure in 
duplicate.  
Melting temperatures of the duplexes were determined by recording their UV-Vis 
absorbance on a Varian Cary 300 Bio instrument equipped with a six-cell 
thermostatted cell holder. Melting curves were monitored at 260 nm with a heating 
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rate of 0.3 ºC/min. The buffer contained 100 mM NaCl and 10 mM phosphate buffer 
(pH 7). Oligonucleotide concentration was 1 μM for each strand. Melting 
temperatures were calculated from the first derivative of a tenth order polynomial 
function that fitted the data. 
X.2.4.4. Singlet oxygen generation  
2 μM of the PS conjugated ONs were dissolved in a 10 mM phosphate buffer (pH 7) 
containing 100 mM of NaCl. ABDA was added before irradiation (100μM) and 
samples were taken at 0, 0.5, 1, 2, 3, 4 and 5 min. Samples were measured using a 
Trinean DropSense96 UV/VIS droplet reader, using 2 μL samples for each 
measurement (each sampling was performed in duplicate). 
 
X.3. Crosslinking experiments 
X.3.1.Crosslinking using the photosensitisers in solution 
Crosslinking reactions where the photosensitisers were externally added were carried 
out at 20 μM oligonucleotide concentration and also at 2 μM, for comparison with the 
crosslinking experiments where the photosensitiser conjugated oligonucleotides were 
used. The oligonucleotides were dissolved in a 10 mM phosphate buffer (pH 7) 
containing 100 mM of NaCl. The externally added photosensitisers were added just 
before starting the irradiation. Stock solutions of the photosensitiser were prepared in 
DMSO (1.96 mM for TriPyCOOH; 923.76 μM for TT1; 2.18 mM for Ce6), diluted 10x in 
water (DMSO for TT1) and added to the solution immediately before irradiation. 
During the crosslinking reaction the temperature was kept constant at 25°C in an 
Eppendorf Thermomixer comfort with constant shaking at 950 rpm. Samples were 
irradiated using an Euromex fiber optic 100 W halogen light source Ek-1 equipped with 
a red filter when necessary and placed 1 cm above the sample. The spectrum when the 
red filter is placed was determined: 
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X.3.2.Crosslinking using the photosensitiser conjugated oligonucleotides 
Crosslinking reactions using the photosensitiser conjugates were carried out under the 
same conditions as the crosslink experiments using the PSs in solution, but in this case 
no external photosensitiser was added.  
X.3.3.Crosslinking using porphyrin containing nanoparticles 
Crosslinking reactions using porphyrin containing NPs were carried out under the same 
conditions as the crosslink experiments using the PSs in solution, but before HPLC 
analysis of the samples, a filtration step using a PTFE filter was included to avoid 
obstruction of the equipment by the nanoparticles. 
X.3.4.Crosslinking using peptide based nanoparticles 
Previous to the crosslinking experiments, the peptide (1 M) and the furan modified 
oligonucleotide (0.17 M) were incubated together at 37ºC for 30 min in 10 mM 
phosphate buffer (pH 7) containing 100 mM of NaCl. After allowing the samples to cool 
down to 25 ºC, the complementary strand and the externally added Ce6 were added 
just before starting the irradiation. In the case that the Ce6 modified peptide is used, no 
external PS is added. In the relevant cases, heparin is also added before irradiation.  
During the crosslinking reaction the temperature was kept constant at 25°C with 
constant shaking at 950 rpm and samples were taken for PAGE analysis. These samples 
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were lyophilised previous analysis, redissolved in 2 L mQ and 18 L formamide and 
kept for a few minutes in a sonic bath to ensure solubilisation of the ODNs.   
X.3.5.Analysis of crosslinking experiments 
Samples were taken at different times for RP HPLC and PAGE analysis. After the 
maximum crosslinking yield was obtained, prolonged irradiation resulted in 
degradation of the crosslinked species. 
X.3.5.1. RP HPLC analysis 
Crosslinking samples where the photosensitiser was externally added were 
analysed by RP-HPLC equipped with a XBridge C18 column. Crosslinking 
samples with the photosensitizer conjugated to the oligonucleotide were 
measured with the RP HPLC equipped with a Discovery Wide Pore C5 column. 
Crosslinking yields were determined by integration of the corresponding 
peaks in the HPLC chromatogram and by comparing the area of the peak of 
the crosslinked species with the peak of the limiting single oligonucleotide 
strand, both corrected for their extinction coefficient. The extinction 
coefficient of the duplex was calculated based on the method described by 
R. Owczarzy et al.(5). 
 
X.3.5.2. PAGE analysis 
Samples were analysed by denaturing gel electrophoresis. The gels were prepared 
by dissolving 4,2 g urea in 5 mL of 40% acrylamide:bisacrylamide (19:1) and 1 mL 
10x TBE buffer. 100 μL of a 0,5 M solution of ammonium persulphate was added 
and the solution was diluted to 10 mL with milliQ water. After cooling the solution, 
N,N,N’,N’- tetramethylethylenediamine was added and the resulting mixture was 
poured between glass plates and allowed to polymerize for one hour. The gels were 
subjected to a pre-run in the consort EV202 at a voltage power of 225V during half 
an hour. After mixing the samples with formamide in 9:1 formamide:sample ratio , 
they were loaded on the gel. During a run of approximately one hour, the 
temperature was kept at 25°C with a Julabo F12. The gels were stained with 
GelRedTM or GelGreenTM Nucleic acid gel stain (VWR) and photographed using an 
Autochemi imaging system. 
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X.4. Peptide materials and methods.  
X.4.1.Synthesis of MPG-8 
MPG-8 was synthesised by Jos Van de Begin following a modified version of the protocol 
previously reported (6–8). The synthesis was carried out on solid phase using Cysteamine 4-
methoxytrityl resin on an automated peptide synthesizer (SYRO Multiple Peptide 
Synthesizer equipped with a vortexing unit (Multisyntech, Witten, Germany). The peptide 
was synthesised using a standard Fmoc-tBu strategy. 
X.4.1.1. Cleavage, deprotection and purification 
MPG-8 deprotection was carried out using a mixture 94:2.5:2.5:1 of TFA/H2O/ 
EDT/TIS, allowing to react for 4 hours to ensure deprotection of the Arg residue. 
After this time, the solution was collected, the resin was washed with TFA and the 
two fractions combined and dried under a nitrogen flow. Pre-purification of the 
peptide was carried out by precipitation using cold MTBE, twice. The remaining 
pellet was dried under nitrogen and redissolved in 1:1 ACN/mQ.  
MPG-8 was purified by RP HPLC equipped with a Luna C18 column, linear gradient 
of 0-100% ACN in 15 minutes), lyophilised and redissolved in mQ for mass analysis.  
X.4.1.2. MS analysis 
The peptide was successfully identified by LC-MS analysis by an Agilent 1100 Series 
instrument equipped with a Phenomenex Kinetex C18 100 Å column (150 x 4.6 mm, 
5 μm at 35 °C) with an ES-MSD type VL mass detector (quadrupole ion trap mass 
spectrometer) using a flow rate of 1.5 ml/min (eluent: 0.1% HCOOH in H2O and 
CH3CN). 
X.4.2.Ce6 conjugation to MPG-8 
A mixture of Ce6 (3.6 mg, 2.50 eq), HBTU (2.4 eq) and DIPEA (5 eq) in 300 L DMF were 
added to MPG-8 (5.8 mg, 2.40 mol) still attached to the resin. The reaction mixture 
was allowed to react overnight under argon atmosphere in the darkness. Next, the resin 
was sequentially washed using 500 L of 3xDMF, 3 MeOH and 3x Et2O.  
X.4.2.1. Cleavage, deprotection and purification of Ce6MPG-8 
Ce6MPG-8 was deprotected using a mixture of 0.1M HCl in HFIP (HCl in HFIP/EDT/TIS 
96.5:2.5:1), allowing to react for 4 hours in the darkness under argon atmosphere.  
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After this time, the solution was collected, the resin was washed with HFIP and the 
two fractions combined and dried under a nitrogen flow. Pre-purification of the 
peptide was carried out by precipitation using cold MTBE twice. The remaining 
pellet was dried under nitrogen and redissolved in 1:1 ACN/mQ.  
Ce6MPG-8 was purified by RP HPLC equipped with a Luna C18 column, linear 
gradient of 0-100% ACN in 25 minutes) and the three obtained fractions were 
lyophilised and redissolved in mQ for mass analysis.  
X.4.2.2. MS analysis 
LC-MS analysis of Ce6MPG-8 was unsuccessfully attempted but the correct mass 
could be found by MALDI-TOF in all fractions. The first obtained fraction was used 
for the following experiments for showing a higher purity.  
X.4.3.Size determination of the peptide/ODN nanoparticles.  
The peptide (1 M) and the furan modified oligonucleotide (0.17 M) were incubated 
together at 37ºC for 30 min in 10 mM phosphate buffer (pH 7) containing 100 mM of 
NaCl to allow nanoparticle formation.  
The size of this nanoparticles was assessed by dynamic light scattering (DLS) using a 
Malvern Zetasizer Nano Series running DTS software and operating a 4 mW He-Ne laser 
at 633 nm. Detection was performed at an angle of 173°. 
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X.5. Experimental data 
X.5.1.Experimental data for Chapter III  
X.5.1.1.  Characterisation of synthesised ODNs 
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X.5.1.2. ICL experiments using Ce6 in solution 
  
 
 
Figure 3. HPLC traces of crosslinking experiments using Ce6 (1% DMSO). Top: [duplex] = 2 M, [Ce6] = 2 M; middle: 
[duplex] = 20 M, [Ce6] = 5 M; bottom: [duplex] = 20 M, [Ce6] = 10 M 
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Figure 4. PAGE analysis of crosslinking experiments using Ce6 (1% DMSO). Left: [duplex] = 2 M, [Ce6] = 2 M; middle: 
[duplex] = 20 M, [Ce6] = 5 M; right: [duplex] = 20 M, [Ce6] = 10 M 
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Figure 5. HPLC traces of crosslinking experiments using Ce6 at different DMSO percentage. Top: [duplex] = 20 M, 
[Ce6] = 5 M, no DMSO; bottom: [duplex] = 2 M, [Ce6] = 2 M, 20% DMSO 
 
Figure 6. PAGE analysis of crosslinking experiments using Ce6 at different DMSO percentage. Left: [duplex] = 20 M, 
[Ce6] = 5 M, no DMSO; right: [duplex] = 2 M, [Ce6] = 2 M, 20% DMSO 
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X.5.1.3. ICL experiments using TriPyCOOH in solution 
 
 
 
Figure 7. HPLC traces of crosslinking experiments using TriPyCOOH. Top: [duplex] = 2 M, [TriPyCOOH] = 2 M; middle: 
[duplex] = 20 M, [TriPyCOOH] = 5 M; bottom: [duplex] = 20 M, [TriPyCOOH] = 10 M 
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Figure 8. PAGE analysis of crosslinking experiments using TriPyCOOH. Left: [duplex] = 2 M, [TriPyCOOH] = 2 M; 
middle: [duplex] = 20 M, [TriPyCOOH] = 5 M; right: [duplex] = 20 M, [TriPyCOOH] = 10 M 
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Figure 9. HPLC traces of crosslinking experiments using [duplex] = 20 M, [TriPyCOOH] = 5 M. Top: white light; 
bottom: red light. 
 
 
Figure 10. HPLC traces of crosslinking experiments using [duplex] = 20 M, [TriPyCOOH] = 10 M. Top: white light; 
bottom: red light 
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Figure 11. PAGE analysis of red and white evaluation crosslinking experiments. Top left: [duplex] = 20 M, [TriPyCOOH] 
= 5 M, white light; top right: [duplex] = 20 M, [TriPyCOOH] = 5 M, red light; bottom left: [duplex] = 20 M, 
[TriPyCOOH] = 10 M, white light; bottom right: [duplex] = 20 M, [TriPyCOOH] = 10 M, red light. 
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X.5.1.4. ICL experiments using TT1 in solution 
 
 
 
Figure 12. HPLC traces of crosslinking experiments using TT1. Top: [duplex] = 2 M, [TT1] = 2 M; middle: [duplex] = 
20 M, [TT1] = 5 M; bottom: [duplex] = 20 M, [TT1] = 10 M 
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Figure 13. HPLC traces of crosslinking experiments using TT1. [duplex] = 20 M, [TT1] = 20 M. 
 
 
Figure 14. PAGE analysis using TT1. Top left: [duplex] = 2 M, [TT1] = 2 M; top right: [duplex] = 20 M, [TT1] = 5 M; 
bottom left: [duplex] = 20 M, [TT1] = 10 M; bottom right: [duplex] = 20 M, [TT1] = 20 M 
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X.5.1.5. ICL experiements using a non-nucleobase furan building block. 
 
Figure 15. HPLC traces of crosslinking experiments using Ce6 and FON2/ON1 duplex. [duplex] = 2 M, [Ce6] = 2 M;  
 
Figure 16. HPLC traces of crosslinking experiments using TriPyCOOH and FON2/ON1 duplex. [duplex] = 20 M, 
[TriPyCOOH] = 5 M. 
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Figure 17. HPLC traces of crosslinking experiments using TT1 and FON2/ON1 duplex. [duplex] = 2 M, [TT1] = 2 M. 
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X.5.2.Experimental data for chapter IV  
X.5.2.1. Characterisation of the synthesised ODNs 
 
 
  
min5 10 15 20 25 30 35 40
mAU
0
20
40
60
80
100
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\16-07-13EVA2\EL000006.D)
999.0 2799.4 4599.8 6400.2 8200.6 10001.0
Mass (m/z)
0
1930.0
0
10
20
30
40
50
60
70
80
90
100
%
 I
n
te
n
s
it
y
Voyager Spec #1[BP = 3769.1, 1930]
3769.78
1885.88
3807.53
3816.641982.24
3832.15
Figure 18. Left:  HPLC chromatogram of ON2. Right:  MALDI-TOF MS analysis. Expected mass: 3769 Da. Observed mass: 3770 
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Figure 19. Left: HPLC chromatogram of ON4. Right:  MALDI-TOF MS analysis. Expected mass: 3765 Da. Observed mass: 3767 Da 
 
m in5 10 15 20 25 30 35 40
mAU
0
50
100
150
200
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\14-11-19\EL000001.D)
999.0 2799.4 4599.8 6400.2 8200.6 10001.0
Mass (m/z)
0
1828.0
0
10
20
30
40
50
60
70
80
90
100
%
 I
n
te
n
s
it
y
Voyager Spec #1[BP = 3766.2, 1828]
3766.99
3804.79
1883.77
3905.84
7534.943835.99
Figure 20. Left: HPLC chromatogram of ON5. Right:  MALDI-TOF MS analysis. Expected mass: 3765 Da. Observed mass: 3767 Da 
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Figure 21. Left:  HPLC chromatogram of ON6. Right:  MALDI-TOF MS analysis. Expected mass: 3765 Da. Observed mass: 3767 Da 
m in5 10 15 20 25 30 35 40
mAU
0
50
100
150
200
250
300
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\14-11-19\EL000025.D)
999.0 2799.4 4599.8 6400.2 8200.6 10001.0
Mass (m/z)
0
1050.0
0
10
20
30
40
50
60
70
80
90
100
%
 I
n
te
n
s
it
y
Voyager Spec #1[BP = 3767.7, 1050]
3767.06
1883.74
3804.74
3634.82
7536.653518.45
3904.46
Figure 22. Left: HPLC chromatogram of ON7. Right:  MALDI-TOF MS analysis. Expected mass: 3765 Da. Observed mass: 3767 Da 
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Figure 23. Left: HPLC chromatogram of FON3. Right:  MALDI-TOF MS analysis. Expected mass: 3659 Da. Observed mass: 3660 Da 
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X.5.2.2. Characterisation of the photosensitiser conjugates 
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Figure 24. a) HPLC chromatograms of purified PON1 at 260 and 400 nm using a Discovery BIO Wide Pore C5 
column. b) MALDI-TOF analysis. Observed mass: 4347 Da. Expected mass: 4347 Da 
Figure 25. a) HPLC chromatograms of purified PON2 at 260 and 420 nm analysed using an Aeris Wide Pore 
column. b) MALDI-TOF analysis. Observed mass: 4412 Da. Expected mass: 4412 Da 
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Figure 26. a) HPLC chromatograms of purified PON3 at 260 and 680 nm analysed using a Discovery BIO Wide Pore 
C5 column. Double signal is appearing due to the fact that TT1 is used as a regioisomeric mixture. b) MALDI-TOF 
analysis. Observed mass: 4540 Da. Expected mass: 4539 Da. 
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Figure 27. PON4 MALDI-TOF MS analysis. Expected mass: 4370 Da. Observed mass: 4372 Da 
 
Figure 28. PON5 MALDI-TOF MS analysis. Expected mass: 4408 Da. Observed mass: 4408 Da 
 
Figure 29. PON6 MALDI-TOF MS analysis. Expected mass: 4408 Da. Observed mass: 4409 Da 
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Figure 30. PON7 MALDI-TOF MS analysis. Expected mass: 4408 Da. Observed mass: 4408 Da 
 
 
Figure 31. PON8 MALDI-TOF MS analysis. Expected mass: 4408 Da. Observed mass: 4409 Da 
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X.5.2.3. ICL experiments using photosensitiser conjugates and FON1 
 
Figure 32. HPLC traces at 260 nm of ICL experiments using PON1/FON1 at 2 M concentration. 
 
 
Figure 33. HPLC traces at 260 nm of ICL experiments using PON2/FON1 at 2 M concentration. 
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Figure 34. Top: HPLC traces at 260 nm of ICL experiments using PON3/FON1 at 2 M concentration. Bottom: zoom in 
of the region where the crosslinked adduct appears. 
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Figure 35. HPLC traces at 260 nm of ICL experiments using PON4/FON1 at 2 M concentration. 
 
X.5.2.4. ICL experiments at lower temperature  
 
 
Figure 36. HPLC traces at 260 nm of ICL experiments using PON1/FON1 at 2 M concentration at 10ºC. 
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Figure 37. HPLC traces at 260 nm of ICL experiments using PON2/FON1 at 2 M concentration at 10ºC. 
 
 
Figure 38. Top: HPLC traces at 260 nm of ICL experiments using PON3/FON1 at 2 M concentration at 10ºC. Bottom: 
zoom in of the region where the crosslinked adduct appears.  
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X.5.2.5. ICL experiments using a non-nucleobase furan building block 
 
Figure 39. HPLC traces at 260 nm of ICL experiments using PON1/FON2 at 2 M concentration. 
 
Figure 40. HPLC traces at 260 nm of ICL experiments using PON2/FON2 at 2 M concentration. 
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Figure 41. Top: HPLC traces at 260 nm of ICL experiments using PON3/FON2 at 2 M concentration. Bottom: zoom in 
of the region where the crosslinked adduct appears.  
 
Figure 42. MALDI-TOF analysis of PON3/FON2 crosslinked adduct. Expected mass: 8237 Da; observed mass: 8238 Da 
min8 10 12 14 16 18 20 22 24
mAU
0
10
20
30
40
50
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\15-04-08EVA\EL000008.D)
  A
re
a:
 6
7.
87
34
 2
2
.2
1
0
  A
re
a:
 7
3.
50
25
 2
2
.9
0
9
min8 10 12 14 16 18 20 22 24
mAU
0
10
20
30
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\15-04-08EVA\EL000009.D)
  A
re
a:
 7
.1
99
12
 2
1
.7
0
8
  A
re
a:
 5
9.
02
05
 2
2
.1
8
1
  A
re
a:
 6
5.
89
72
 2
2
.8
7
9
min8 10 12 14 16 18 20 22 24
mAU
0
10
20
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\15-04-08EVA\EL000010.D)
  A
re
a:
 1
0.
41
24
 2
1
.6
9
8
  A
re
a:
 5
.7
05
48
 2
2
.0
7
1
  A
re
a:
 7
.1
99
16
 2
2
.1
7
7
  A
re
a:
 3
7.
03
23
 2
2
.8
7
5
min8 10 12 14 16 18 20 22 24
mAU
0
10
20
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\15-04-08EVA\EL000011.D)
  A
re
a:
 1
2.
63
11
 2
1
.6
8
6
  A
re
a:
 7
.5
77
18
 2
2
.0
3
1
  A
re
a:
 6
.0
20
77
 2
2
.3
0
1
  A
re
a:
 2
5.
55
04
 2
2
.8
7
4
min20 21 22 23 24 25 26
mAU
0
2
4
6
8
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\15-04-08EVA\EL000008.D)
  A
re
a:
 1
78
.5
5
 2
2
.9
0
9
min20 21 22 23 24 25 26
mAU
-6
-4
-2
0
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\15-04-08EVA\EL000009.D)
  A
re
a:
 1
3.
07
14
 2
2
.0
5
7
  A
re
a:
 1
00
.1
49
 2
2
.8
7
9
min20 21 22 23 24 25 26
mAU
-5
-4
-3
-2
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\15-04-08EVA\EL000010.D)
  A
re
a:
 2
8.
73
45
 2
2
.0
7
1
  A
re
a:
 6
6.
79
25
 2
2
.8
7
5
min20 21 22 23 24 25 26
mAU
-5
-4
-3
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\15-04-08EVA\EL000011.D)
  A
re
a:
 2
4.
41
46
 2
1
.9
9
5
  A
re
a:
 5
3.
70
7
 2
2
.8
7
4
999.0 3199.4 5399.8 7600.2 9800.6 12001.0
Mass (m/z)
0
563
0
10
20
30
40
50
60
70
80
90
100
%
 I
n
te
n
s
it
y
Voyager Spec #1[BP = 1114.7, 563]
1114.71
1094.42
1318.38
1075.86
1223.31
1278.69
1295.20
8237.981835.18
1237.69
1403.26 1872.41
1333.53
1355.30
1679.47
4119.61
1766.46
1436.43 1950.94
2287.561564.03
2798.662263.24
4542.03
2621.441719.12
2007.63
8276.312582.23
2051.06 4140.75
2648.612125.48
4088.783012.62
2222.43 8258.18
2813.35 4161.262197.81 6614.411049.96
3328.962823.50 4391.43 8299.20
3407.812710.17 4107.95 8312.685028.974568.42
3234.70
5018.60 8417.384292.793846.03
5661.333056.16
8527.094879.894057.42
3374.53
8543.735538.214821.62 6906.453940.40 5991.63 8102.874756.013438.11 8685.195366.95 9656.996881.926275.413993.72
8064.285585.82 8927.264787.93 7570.016119.56 7094.543756.24 6575.11
10385.019229.077810.535392.17 6066.07 6739.03 7253.23 9691.28 10419.315886.62 9716.037231.18 10924.78
PON3 
FON2 t=0 
t=1’ 
t=3’ 
t=5’ 
ICL 
PON3 t=0 
t=1’ 
t=3’ 
t=5’ 
ICL 
158 
 
X.5.2.6. Distance evaluation ICL experiments  
 
Figure 43. HPLC traces at 260 nm of ICL experiments using PON5/FON3 at 2 M concentration. 
 
Figure 44. HPLC traces at 260 nm of ICL experiments using PON6/FON3 at 2 M concentration. 
 
Figure 45. HPLC traces at 260 nm of ICL experiments using PON7/FON3 at 2 M concentration. 
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Figure 46. HPLC traces at 260 nm of ICL experiments using PON8/FON3 at 2 M concentration. 
 
X.5.3.Experimental data for chapter V 
X.5.3.1. Characterisation of the synthesised ODNs 
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Figure 47. Left: HPLC chromatogram of FON5 after preliminary Seppak purification. Right:  MALDI-TOF MS analysis. Expected mass: 
3765 Da. Observed mass: 3767 Da 
Figure 48. HPLC chromatogram of FON4 after preliminary Seppak purification. Right:  MALDI-TOF MS analysis. Expected mass: 
3979 Da. Observed mass: 3980 Da 
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X.5.3.2.  Characterisation of the photosensitiser conjugates 
 
Figure 50. MALDI-TOF analysis of the conjugation between FON5 and TriPyCOOH. The expected mass (4504 Da) could 
not be observed. 
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Figure 49. MALDI-TOF analysis of the conjugation between FON5 and Ce6. The expected mass (4439 Da) could not be observed. 
Right: zoom in of the broad signal. 
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Figure 51. MALDI-TOF analysis of the conjugation between FON5 and TT1. The expected mass (4631 Da) could be observed within 
the boar signal. Right: zoom in of the broad signal. 
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X.5.3.3. ICL experiments using Ce6 self-activating probe 
 
Figure 53. HPLC traces at 260 nm of ICL experiments using Ce6-FON4/ON1 at 2 M concentration. 
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Figure 52. MALDI-TOF analysis of the conjugation between FON4 and Ce6. The observed mass (4574 Da) corresponds to the oxidised 
probe (non-oxidised expected =4556 Da) 
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X.5.3.4. ICL experiment using TT1 self-activating probe  
 
Figure 54. HPLC traces at 260 nm of ICL experiments using TT1-FON5/ON1 at 2 M concentration. 
X.5.3.5. ICL experiments using the templated system  
 
Figure 55. HPLC traces of ICL experiments using the templated ON1/ON9/FON3 at 200 nM concentration and Ce6 at 
20 M concentration. 
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Figure 56. HPLC traces of ICL experiments using the templated ON1/ON9/FON3 at 200 nM concentration and Ce6 at 
200 nM concentration. 
 
Figure 57. PLC traces of ICL experiments using the PON1/ON9/FON3 templated system at 200 nM concentration.  
  
min6 8 10 12 14 16 18 20
mAU
0
5
10
15
20
25
30
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\17-03-10EVA3\EL000003.D)
min6 8 10 12 14 16 18 20
mAU
0
5
10
15
20
25
30
35
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\17-03-10EVA3\EL000004.D)
min6 8 10 12 14 16 18 20
mAU
0
5
10
15
20
25
30
35
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\17-03-10EVA3\EL000005.D)
min15 20 25 30 35
mAU
0
10
20
30
40
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\17-03-31EVA2\EL000005.D)
min15 20 25 30 35
mAU
0
20
40
60
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\17-03-31EVA2\EL000006.D)
min15 20 25 30 35
mAU
0
20
40
60
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\17-03-31EVA2\EL000007.D)
min15 20 25 30 35
mAU
0
20
40
60
 DAD1 A, Sig=260,16 Ref=off (D:\DATA\17-03-31EVA2\EL000008.D)
FON3 ON1 t=0 ON9 
t=3’ 
t=10’ 
FON3 PON1 
t=0 
ON9 
t=3’ 
t=10’ 
t=5’ 
164 
 
X.5.4.Experimental data for chapter VI 
X.5.4.1. Characterisation of the synthesised peptide 
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Figure 58. LC-MS analysis of MPG-8 peptide. Expected mass: 2463.3 Da. Observed mass: 2464 Da. Top left: RP HPLC chromatogram; top 
right: ESI-MS spectrum; bottom left: trace of multiply charged ions of MPG-8; bottom right: deconvoluted mass of MPG-8. 
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X.5.4.2. Characterisation of the synthesised peptide conjugate 
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Figure 59. Top left: RP HPLC analysis of Ce6MPG-8, before purification; top right: RP HPLC analysis of Ce6MPG-8 after purification, 
where three fractions were separated; bottom: MALDI-TOF analysis of Ce6MPG-8 (F1), expected mass: 3042 Da, observed mass: 3049 
Da. 
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